<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Plants (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Plants (Basel)</journal-id><journal-id journal-id-type="publisher-id">plants</journal-id><journal-title-group><journal-title>Plants</journal-title></journal-title-group><issn pub-type="epub">2223-7747</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7766900</article-id><article-id pub-id-type="pmid">33339267</article-id><article-id pub-id-type="doi">10.3390/plants9121784</article-id><article-id pub-id-type="publisher-id">plants-09-01784</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Multi-Therapeutic Potential of Naringenin (4&#x02032;,5,7-Trihydroxyflavonone): Experimental Evidence and Mechanisms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arafah</surname><given-names>Azher</given-names></name><xref ref-type="aff" rid="af1-plants-09-01784">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9995-6576</contrib-id><name><surname>Rehman</surname><given-names>Muneeb U.</given-names></name><xref ref-type="aff" rid="af1-plants-09-01784">1</xref><xref ref-type="aff" rid="af2-plants-09-01784">2</xref><xref rid="c1-plants-09-01784" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7294-3660</contrib-id><name><surname>Mir</surname><given-names>Tahir Maqbool</given-names></name><xref ref-type="aff" rid="af3-plants-09-01784">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1555-2820</contrib-id><name><surname>Wali</surname><given-names>Adil Farooq</given-names></name><xref ref-type="aff" rid="af4-plants-09-01784">4</xref><xref rid="c1-plants-09-01784" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Rayeesa</given-names></name><xref ref-type="aff" rid="af2-plants-09-01784">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6725-0686</contrib-id><name><surname>Qamar</surname><given-names>Wajhul</given-names></name><xref ref-type="aff" rid="af5-plants-09-01784">5</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Rehan</given-names></name><xref ref-type="aff" rid="af6-plants-09-01784">6</xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Ajaz</given-names></name><xref ref-type="aff" rid="af1-plants-09-01784">1</xref></contrib><contrib contrib-type="author"><name><surname>Aga</surname><given-names>Syed Sameer</given-names></name><xref ref-type="aff" rid="af7-plants-09-01784">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3839-8187</contrib-id><name><surname>Alqahtani</surname><given-names>Saeed</given-names></name><xref ref-type="aff" rid="af1-plants-09-01784">1</xref></contrib><contrib contrib-type="author"><name><surname>Almatroudi</surname><given-names>Nada M.</given-names></name><xref ref-type="aff" rid="af8-plants-09-01784">8</xref></contrib></contrib-group><aff id="af1-plants-09-01784"><label>1</label>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; <email>aazher@ksu.edu.sa</email> (A.A.); <email>aajaz@ksu.edu.sa</email> (A.A.); <email>saeed@ksu.edu.sa</email> (S.A.)</aff><aff id="af2-plants-09-01784"><label>2</label>Division of Veterinary Biochemistry, Faculty of Veterinary Science and Animal Husbandry, SKUAST-Kashmir, Alustang, Shuhama 190006, India; <email>alirayeesa@gmail.com</email></aff><aff id="af3-plants-09-01784"><label>3</label>National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA; <email>tmmir@olemiss.edu</email></aff><aff id="af4-plants-09-01784"><label>4</label>Department of Pharmaceutical Chemistry, RAK College of Pharmaceutical Sciences, RAK Medical and Health Science University, Ras Al Khaimah 11171, UAE</aff><aff id="af5-plants-09-01784"><label>5</label>Department of Pharmacology &#x00026; Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; <email>wqidris@ksu.edu.sa</email></aff><aff id="af6-plants-09-01784"><label>6</label>Department of Nano-Therapeutics, Institute of Nano-Science and Technology (DST-INST), Mohali 160047, India; <email>rehankhan@inst.ac.in</email></aff><aff id="af7-plants-09-01784"><label>7</label>Department of Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (NGHA), Jeddah 21423, Saudi Arabia; <email>agas@ksau-hs.edu.sa</email></aff><aff id="af8-plants-09-01784"><label>8</label>Department of Clinical Pharmacy, College of Pharmacy Girls Campus, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; <email>439204163@student.ksu.edu.sa</email></aff><author-notes><corresp id="c1-plants-09-01784"><label>*</label>Correspondence: <email>muneebjh@gmail.com</email> (M.U.R); <email>farooq@rakmhsu.ac.ae</email> (A.F.W.)</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>9</volume><issue>12</issue><elocation-id>1784</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Extensive research has been carried out during the last few decades, providing a detailed account of thousands of discovered phytochemicals and their biological activities that have the potential to be exploited for a wide variety of medicinal purposes. These phytochemicals, which are pharmacologically important for clinical use, primarily consist of polyphenols, followed by terpenoids and alkaloids. There are numerous published reports indicating the primary role of phytochemicals proven to possess therapeutic potential against several diseases. However, not all phytochemicals possess significant medicinal properties, and only some of them exhibit viable biological effects. Naringenin, a flavanone found in citrus fruits, is known to improve immunity, repair DNA damage, and scavenge free radicals. Despite the very low bioavailability of naringenin, it is known to exhibit various promising biological properties of medicinal importance, including anti-inflammatory and antioxidant activities. This review focuses on the various aspects related to naringenin, particularly its physicochemical, pharmacokinetic, and pharmacodynamic properties. Furthermore, various pharmacological activities of naringenin, such as anticancer, antidiabetic, hepatoprotective, neuroprotective, cardioprotective, nephroprotective, and gastroprotective effects, have been discussed along with their mechanisms of action.</p></abstract><kwd-group><kwd>naringenin</kwd><kwd>pharmacology</kwd><kwd>natural medicine</kwd><kwd>phytochemistry</kwd><kwd>polyphenols</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-plants-09-01784"><title>1. Introduction</title><p>Natural products are a rich source of phytochemicals, including polyphenols, which provide a pool of antioxidants for the maintenance of steady health. Polyphenols are categorized based on the structure of phenol rings and functional moieties that interconnect these phenolic rings and hence are divided into flavonoids, lignans, stilbenes, and phenolic acids. Flavonoids, which are mainly natural pigments, are primarily found in plants. They are comprised of a basic phenolic structure [<xref rid="B1-plants-09-01784" ref-type="bibr">1</xref>,<xref rid="B2-plants-09-01784" ref-type="bibr">2</xref>] and have secured a place in folk medicine globally due to their beneficial biological effects [<xref rid="B3-plants-09-01784" ref-type="bibr">3</xref>]. Among over 4000 flavonoids that have been discovered to date, several have been found to exhibit a wide variety of beneficial biological activities. Among them, naringenin has gained much attention lately, as many studies have suggested that several of its biological properties are of medicinal importance [<xref rid="B4-plants-09-01784" ref-type="bibr">4</xref>,<xref rid="B5-plants-09-01784" ref-type="bibr">5</xref>].</p><p>Naringenin (4&#x02032;,5,7-trihydroxyflavonone) is mainly found in citrus fruits (grapefruit and oranges) and tomatoes. It is synthesized from an aromatic amino acid, phenylalanine, and has been found in different conjugated forms, primarily as aglycone, neohesperidoside, and glycosylated forms. Each of these forms differs in its pharmacokinetic (absorption, distribution, metabolism, and elimination) properties. The richest source of naringenin is grapefruits, where it is present as an inactive glycone form called &#x0201c;naringin.&#x0201d; Chemically, naringin is a 4&#x02032;,5,7-trihydroxyflavonone 7-rhamnoglucoside that is hydrolyzed by the intestinal bacterial naringinase enzyme soon after its ingestion, resulting in the production of two intermediates, rhamnose and naringenin (4&#x02032;,5,7-trihydroxyflavonone&#x02014;the most active aglycone form) [<xref rid="B6-plants-09-01784" ref-type="bibr">6</xref>] (<xref ref-type="fig" rid="plants-09-01784-f001">Figure 1</xref>). Naringenin has been reported to be easily absorbed by the intestinal tract; thus, it becomes rapidly bioavailable in circulation. Because of the rapid absorption, it is the most pharmacologically effective form of naringin [<xref rid="B7-plants-09-01784" ref-type="bibr">7</xref>].</p><p>Naringenin is known to have poor water solubility, which affects its overall bioavailability [<xref rid="B8-plants-09-01784" ref-type="bibr">8</xref>]. The pharmacological activities associated with naringenin have been attributed to its ability to suppress oxidative stress by scavenging free radicals generated during various basal metabolic conditions [<xref rid="B9-plants-09-01784" ref-type="bibr">9</xref>]. Presently, attempts are made for the de novo synthesis of pharmacologically numerous active flavonoids, including naringenin from <italic>Escherichia coli</italic>, in order to ensure their cost-effective high production [<xref rid="B10-plants-09-01784" ref-type="bibr">10</xref>]. In this article, we attempt to review the available scientific literature on various biological and pharmacological properties of naringenin. We exploited two largely available scientific databases, PubMed and Google Scholar, for literature search. The literature was searched using keywords, such as &#x0201c;polyphenols&#x0201d;, &#x0201c;flavonoids&#x0201d;, &#x0201c;aglycone&#x0201d;, &#x0201c;naringin&#x0201d;, &#x0201c;naringenin&#x0201d;, &#x0201c;sources of naringenin&#x0201d;, &#x0201c;forms of naringenin&#x0201d;, &#x0201c;structure activity relationship for naringenin&#x0201d;, &#x0201c;bioavailability of naringenin&#x0201d;, &#x0201c;pharmacokinetics of naringenin&#x0201d;, &#x0201c;pharmacodynamics of naringenin&#x0201d;, &#x0201c;in vitro and in vivo pharmacological properties of naringenin such as anti-cancer, anti-diabetic&#x0201d;, &#x0201c;hepatoprotective&#x0201d;, &#x0201c;neuro-protective&#x0201d;, &#x0201c;cardio-protective&#x0201d;, &#x0201c;nephron-protective&#x0201d;, and &#x0201c;gastro-protective and immune-modulatory effects&#x0201d;. Only a few clinical trials on naringin or naringenin were registered at <uri>clinicaltrials.gov</uri> [<xref rid="B11-plants-09-01784" ref-type="bibr">11</xref>], indicating that tremendous efforts are required for the transition of this natural product from preclinical to clinical use. The information from different research reports was collected and presented in different relevant sections and subsections of this review.</p></sec><sec id="sec2-plants-09-01784"><title>2. Physicochemical Characteristics, Pharmacokinetics, and Pharmacodynamics of Naringenin</title><p>Naringenin has a simple 15-carbon-atom flavonoid skeleton, which comprises three rings. Among them, two benzene rings are linked to a three-carbon chain [<xref rid="B12-plants-09-01784" ref-type="bibr">12</xref>]. The chemical nomenclature of naringenin is 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one or 4&#x02032;,5,7-trihydroxyflavanone, with a molar mass of 272.3 [<xref rid="B13-plants-09-01784" ref-type="bibr">13</xref>]. The major mechanism by which naringenin exhibits its diverse bioactivities is through the suppression of oxidative stress, which is caused by various free radical species produced in the organisms as byproducts of aerobic metabolism. The existence of the 2, 3-double bond linked to the 4-oxo group of naringenin has been demonstrated to be a critical functional active group responsible for its antioxidant potential [<xref rid="B12-plants-09-01784" ref-type="bibr">12</xref>,<xref rid="B14-plants-09-01784" ref-type="bibr">14</xref>].</p><p>Naringenin has a very low affinity for water with a water solubility near 46 &#x000b1; 6 &#x000b5;g/mL, which limits its oral bioavailability to approximately ~5.81%. It undergoes rapid hepatic first-pass metabolism and is transformed into glucuronide intermediary products, resulting in its limited bioavailability in plasma. Sun et al. reported that the t<sub>1/2</sub> of naringenin is about 4.69 h, along with C<sub>max</sub> =&#x02009;2910.6&#x02009;ng/mL and area under curve (AUC)&#x02009; =&#x02009; 40,607.9&#x02009;ng/mL after oral ingestion (Zhi Zhu Wan, a traditional Chinese medicine) [<xref rid="B15-plants-09-01784" ref-type="bibr">15</xref>]. Kanaze et al. reported that the absorption of naringenin reached a peak after 3.5 h of oral consumption in human subjects (135 mg), with Cmax = 2009.51 +/&#x02212; 770.82 ng/mL and AUC (0-infinity) = 9424.52 +/&#x02212; 2960.52 ng h/mL [<xref rid="B16-plants-09-01784" ref-type="bibr">16</xref>]. The authors suggested that, despite its fast absorption, the bioavailability of naringenin remained low due to extensive first-pass metabolism in the intestine. After oral intake of naringin or grapefruit juice, significant concentrations of naringenin have been found in peripheral blood and urine [<xref rid="B8-plants-09-01784" ref-type="bibr">8</xref>]. Recently, researchers have utilized different techniques and complex inclusion methods to develop numerous viable naringenin formulations. These techniques include liposomes, nanoparticles, self-nano-emulsifying drug delivery systems (SNEDDS), and nanosuspensions to improve its bioavailability, which would enhance its clinical applications [<xref rid="B17-plants-09-01784" ref-type="bibr">17</xref>,<xref rid="B18-plants-09-01784" ref-type="bibr">18</xref>].</p><p>Naringenin is relatively safe with LD50 of 5000 mg/kg [<xref rid="B19-plants-09-01784" ref-type="bibr">19</xref>]. The chief mechanism of action of naringenin is the inhibition of specific cytochrome P450 isoforms&#x02014;CYP1A2 [<xref rid="B20-plants-09-01784" ref-type="bibr">20</xref>] and CYP3A4 in humans [<xref rid="B21-plants-09-01784" ref-type="bibr">21</xref>]. Naringenin has successfully demonstrated antagonistic activities on all types of opioid receptors [<xref rid="B22-plants-09-01784" ref-type="bibr">22</xref>]. It has positive health effects in humans; concurred by numerous research reports indicating that it has hepatoprotective [<xref rid="B23-plants-09-01784" ref-type="bibr">23</xref>], anti-mutagenic [<xref rid="B24-plants-09-01784" ref-type="bibr">24</xref>], anti-carcinogenic [<xref rid="B25-plants-09-01784" ref-type="bibr">25</xref>], antioxidant [<xref rid="B26-plants-09-01784" ref-type="bibr">26</xref>], anti-diabetic [<xref rid="B27-plants-09-01784" ref-type="bibr">27</xref>], and antiatherogenic [<xref rid="B28-plants-09-01784" ref-type="bibr">28</xref>] activities (<xref ref-type="fig" rid="plants-09-01784-f002">Figure 2</xref>). The daily dietary requirement of flavonoids has been considered to be a few hundred milligrams [<xref rid="B29-plants-09-01784" ref-type="bibr">29</xref>]. Its role against inflammation and oxidative injuries makes it a potential candidate for the treatment of various oxidative-stress-related disorders [<xref rid="B22-plants-09-01784" ref-type="bibr">22</xref>,<xref rid="B23-plants-09-01784" ref-type="bibr">23</xref>,<xref rid="B24-plants-09-01784" ref-type="bibr">24</xref>,<xref rid="B25-plants-09-01784" ref-type="bibr">25</xref>,<xref rid="B26-plants-09-01784" ref-type="bibr">26</xref>,<xref rid="B27-plants-09-01784" ref-type="bibr">27</xref>,<xref rid="B28-plants-09-01784" ref-type="bibr">28</xref>,<xref rid="B29-plants-09-01784" ref-type="bibr">29</xref>].</p></sec><sec id="sec3-plants-09-01784"><title>3. Pharmacological Properties of Naringenin</title><sec id="sec3dot1-plants-09-01784"><title>3.1. Anticancer Properties</title><p>Cancer is one of the leading causes of death worldwide [<xref rid="B30-plants-09-01784" ref-type="bibr">30</xref>]. Mutations of DNA, caused by any exogenous stimulus or an endogenous anomaly, in normal cells can result in the uncontrolled division of cells, leading to tumor development and progression. Chemotherapeutic agents appear to exert anti-cancerous activity by assisting in cell apoptosis [<xref rid="B31-plants-09-01784" ref-type="bibr">31</xref>]. However, the devastating effects of the chemotherapy on the living system are colossal; i.e., every healthy cell and primarily rapidly dividing cells, including gastric mucosa, hair follicle, and bone marrow cells, are deleteriously affected in this process, which restricts their normal functioning [<xref rid="B32-plants-09-01784" ref-type="bibr">32</xref>]. Therefore, toxicity appears to be the most limiting feature associated with the chemotherapeutic agents of synthetic origin. On the other hand, therapeutically active plant-derived products/components are considered minimally toxic while having significant pharmacological attributes [<xref rid="B33-plants-09-01784" ref-type="bibr">33</xref>,<xref rid="B34-plants-09-01784" ref-type="bibr">34</xref>]. Globally, the anti-cancer potential of flavonoid &#x0201c;naringenin&#x0201d; has been widely debated [<xref rid="B25-plants-09-01784" ref-type="bibr">25</xref>]. The case-controlled study conducted by Stefani et al. in Uruguay has reported an approximately 70% decrease in cancer risk associated with the esophagus, larynx, oral cavity, and pharynx after naringenin administration [<xref rid="B35-plants-09-01784" ref-type="bibr">35</xref>] (<xref ref-type="fig" rid="plants-09-01784-f003">Figure 3</xref>).</p><p>The appraisal discussed below of naringenin can help in better understanding the molecular mechanisms behind its anti-cancer activities.</p><p>Naringenin causes carcinogen inactivation by upregulation of the Uridine 5&#x02019;-diphospho glucuronosyltransferase, QR, and GST that help in the removal of carcinogens in the body. By inhibition of CYP19, it helps to control breast and prostate cancer. It has anti-proliferative properties exhibited by downregulation of ROS and ODC, and signal transduction enzymes like PTK, PKC, and PIP3 decrease the unwanted proliferation of cells. Naringenin causes cell cycle arrest in G and S phases in cancer cells by inhibiting cyclin, and CDK helps to control leukemia. The increase in caspase, cytochrome, and BAX and the downregulation of BCL2 in mitochondria are caused by naringenin, and the inhibition of ER&#x003b1;-dependent mitogenic signaling cascades activation (e.g., phosphoinositide 3-kinase/AKT) or by induction of ER&#x003b1;-dependent p38 kinase activation causes pro-apoptotic activities in cancer cells. Naringenin exhibits its angio-inhibitory effect by decreasing vascular endothelial growth factor (VGFG) and downregulating the TGF-&#x003b2; pathway, thereby decreasing metastasis and invasion in pancreatic cells.</p><sec id="sec3dot1dot1-plants-09-01784"><title>3.1.1. Carcinogen Inactivation</title><p>Human enzymes make a significant contribution to the metabolic conversion of pro-carcinogens into active carcinogens. This transformation is largely executed via cytochrome P450. Naringenin antagonizes this conversion and therefore prevents carcinogenesis and damage to the cells [<xref rid="B36-plants-09-01784" ref-type="bibr">36</xref>]. Naringenin is also known to inhibit the activity of enzyme aromatase (CYP19), which leads to a decrease in the biosynthesis of estrogen. The anti-estrogenic effects so produced may prove to be of significant anti-prostate- and anti-breast-cancer potential [<xref rid="B37-plants-09-01784" ref-type="bibr">37</xref>]. In estrogen-dependent breast cancer, naringenin has exhibited inhibitory effects on estrogen synthetase enzyme (aromatase), which is involved in the biosynthesis of estrogen, thereby reducing cancer-promoting stimulatory effects of estrogens [<xref rid="B38-plants-09-01784" ref-type="bibr">38</xref>,<xref rid="B39-plants-09-01784" ref-type="bibr">39</xref>].</p></sec><sec id="sec3dot1dot2-plants-09-01784"><title>3.1.2. Anti-Proliferative Action</title><p>The mechanism of carcinogenesis takes place in two distinct stages: initiation and progression. The progression stage of carcinogenesis involves products of several genes (especially tumor suppressors) [<xref rid="B40-plants-09-01784" ref-type="bibr">40</xref>], which can serve as specific targets for naringenin to prevent or stop cancer development. Investigations have revealed that the generation of ROS (reactive oxygen species) is one of the key mechanisms responsible for promoting different stages of cancer [<xref rid="B41-plants-09-01784" ref-type="bibr">41</xref>]. Naringenin, as an antioxidant, does efficiently counter such effects. Additionally, restriction to the formation of precancerous lesions via regulation of hyperproliferation has also been reported as one of the bio-effects of naringenin [<xref rid="B42-plants-09-01784" ref-type="bibr">42</xref>].</p><p>Anti-proliferative action of flavonoids has been demonstrated in numerous in vitro studies using various kinds of cancer cells [<xref rid="B43-plants-09-01784" ref-type="bibr">43</xref>,<xref rid="B44-plants-09-01784" ref-type="bibr">44</xref>]. Naringenin inhibits xanthine oxidase [<xref rid="B45-plants-09-01784" ref-type="bibr">45</xref>] cyclooxygenase, lipoxygenase [<xref rid="B46-plants-09-01784" ref-type="bibr">46</xref>] and hampers the proliferation of tumor cells. In experimentally induced colon cancer, naringenin has been reported to inhibit hyperproliferation. Inhibition of ornithine decarboxylase (ODC) activity, in several tissues, by naringenin has also been reported. ODC is involved in the biosynthesis of polyamine, and thus inhibited ODC activity results in the consequent decrease in polyamine and reduced DNA/protein synthesis [<xref rid="B47-plants-09-01784" ref-type="bibr">47</xref>]. Furthermore, naringenin has shown inhibitory effects on signal transduction enzymes, playing an important role in controlling cell growth by regulating proteins like protein tyrosine kinase (PTK) [<xref rid="B48-plants-09-01784" ref-type="bibr">48</xref>,<xref rid="B49-plants-09-01784" ref-type="bibr">49</xref>] protein kinase C (PKC) [<xref rid="B50-plants-09-01784" ref-type="bibr">50</xref>], and phosphoinositide 3-kinases (PIP3) [<xref rid="B51-plants-09-01784" ref-type="bibr">51</xref>]. N-nitrosodiethanolamine (NDEA)-induced hepatocarcinogenic rats after pre- and post-treatment with naringenin have revealed a decline in proliferating cell nuclear antigen (PCNA), which is one of the important markers of hyperproliferation [<xref rid="B52-plants-09-01784" ref-type="bibr">52</xref>,<xref rid="B53-plants-09-01784" ref-type="bibr">53</xref>,<xref rid="B54-plants-09-01784" ref-type="bibr">54</xref>]. Naringenin has been found to suppress the rate of PCNA expression in leukemia cell line HL-60, thereby indicating its anti-proliferative activity [<xref rid="B55-plants-09-01784" ref-type="bibr">55</xref>].</p></sec><sec id="sec3dot1dot3-plants-09-01784"><title>3.1.3. Cell Cycle Arrest</title><p>In response to growth-stimulating signals, cells progress through the various distinct stages of the cell cycle like G1, S, G2, and M, each of which is regulated by activated cyclin-dependent kinases (CDKs). CDKs are activated after adhering to a family of proteins called cyclins. For each phase of the cell cycle, there are diverse stage-specific groups of cyclins and CDKs. There are two families of CDK inhibitors, including p21, p27, and p57, which regulate the cell cycle. Mutation in any of the cell-cycle-regulating genes results in either overexpression or dysregulation of cyclins/CDKs, thus assisting the progression of cancerous cells into the uncontrolled mass of dividing cells. In vitro studies have revealed that naringenin exhibited anti-cancer activity by arresting the cell cycle at the G0/G1 phase along with the induction of apoptosis [<xref rid="B56-plants-09-01784" ref-type="bibr">56</xref>]. It has been also shown to arrest the growth in K562 human leukemia cell line, particularly in the G0/G1 phase of the cell cycle. The inhibition may be achieved via upregulation of p53-independent p21/WAF1. Suppression of cyclin E/CDK2 and Cyclin A/ CDK2 has also been reported [<xref rid="B52-plants-09-01784" ref-type="bibr">52</xref>].</p></sec><sec id="sec3dot1dot4-plants-09-01784"><title>3.1.4. Induction of Apoptosis</title><p>Cancers arise due to dysregulated apoptosis in addition to the change of other pathways like upregulation of growth-promoting oncogenes and downregulation of tumor suppressor genes. Similarly, cell apoptosis, like cell growth, is also tightly regulated by certain promoter and inhibitor genes. Apoptosis does involve several genes for two specific pathways, including intrinsic (<italic>BAX, BAK, APAF-1,</italic> and caspase family) and extrinsic (<italic>TRAIL, TRADD, FADD, FAS,</italic> etc.) pathways. Activation of caspases such as 3 and 9, following release of cytochrome-c, happens to be the pathway that flavonoids trace for inducing apoptosis [<xref rid="B57-plants-09-01784" ref-type="bibr">57</xref>]. Naringenin is believed to inhibit unregulated growth in different cancer cell types executing apoptosis, such as in K562 cell line containing ER&#x003b1; or ER&#x003b2; receptors [<xref rid="B58-plants-09-01784" ref-type="bibr">58</xref>,<xref rid="B59-plants-09-01784" ref-type="bibr">59</xref>]. The pro-apoptotic action on cell lines expressing ER&#x003b1; is either by the inhibition of ER&#x003b1;-dependent mitogenic signaling cascade activation (e.g., phosphoinositide 3-kinase/AKT) or by induction of ER&#x003b1;-dependent p38 kinase activation (a member of the mitogen activating protein kinase family) [<xref rid="B58-plants-09-01784" ref-type="bibr">58</xref>,<xref rid="B60-plants-09-01784" ref-type="bibr">60</xref>]. The possible mechanisms behind the programmed cell death may be the downregulation of Bcl-2 and the upregulation of Bax and Caspase activity [<xref rid="B52-plants-09-01784" ref-type="bibr">52</xref>]. Western blot analysis of the naringenin-treated cells has shown an enhanced concentration of pro-apoptotic protein Bad and a diminished concentration of anti-apoptosis proteins like Bcl-2 [<xref rid="B61-plants-09-01784" ref-type="bibr">61</xref>]. It has been also found that naringenin modulates cellular membrane biophysical parameters such as membrane fluidity, membrane protein and bilayer structures, lipid molecule packaging, and hydration and thereby induces mitochondrial potential and promotes apoptotic activity [<xref rid="B62-plants-09-01784" ref-type="bibr">62</xref>].</p></sec><sec id="sec3dot1dot5-plants-09-01784"><title>3.1.5. Inhibition of Sustained Angiogenesis</title><p>For tumor progression, angiogenesis or neovascularization is a crucial step as it provides essential nutrient supply to the transformed cells. Equilibrium between angiogenic and anti-angiogenic proteins act as a barrier for tumor growth and progression. Angiogenic proteins include VEGF, basic fibroblast growth factor, IL8, and TGF-&#x003b2; [<xref rid="B63-plants-09-01784" ref-type="bibr">63</xref>,<xref rid="B64-plants-09-01784" ref-type="bibr">64</xref>], whereas anti-angiogenic factors include thrombospondin-1, angiostatin, and endostatin. Flavonoids such as naringenin act as effective inhibitors of angiogenesis and hence are regarded as a good treatment for the control of malignancies [<xref rid="B65-plants-09-01784" ref-type="bibr">65</xref>]. Naringenin exhibits its angio-inhibitory effect by decreasing vascular endothelial growth factor (VEFG) and other related factors [<xref rid="B66-plants-09-01784" ref-type="bibr">66</xref>]. It has also been reported to cause downregulation of TGF-&#x003b2; pathway, thereby decreasing metastasis and invasion in pancreatic cells [<xref rid="B67-plants-09-01784" ref-type="bibr">67</xref>].</p></sec></sec><sec id="sec3dot2-plants-09-01784"><title>3.2. Anti-Diabetic Activity</title><p>Diabetes is a metabolic disorder of endocrine origin identified by elevated blood glucose levels. It has been estimated to be the major cause of global morbidities and mortalities linked to diabetes-related afflictions [<xref rid="B68-plants-09-01784" ref-type="bibr">68</xref>]. The disease has two major types, i.e., type 1 and type 2. The former is caused by inadequate or no insulin production, and the latter is caused by insulin deficiency and/or relative insufficiency because of &#x003b2; cell abnormality and compromised response to insulin [<xref rid="B68-plants-09-01784" ref-type="bibr">68</xref>].</p><p>Hyperglycemia, or high blood glucose levels in the body, is the primary indication of diabetes. Glucose and maltose are the catabolic byproducts of starch [<xref rid="B69-plants-09-01784" ref-type="bibr">69</xref>], which are in turn catalyzed by &#x003b1;-glucosidase and &#x003b1;-amylase. It has been reported that inhibition of the activity of these key enzymes can result in the decreased levels of blood glucose. Utilization of these enzyme targets can serve as potential remedies for improving diabetes-related disorders. Naringenin has been found to possess effective anti-diabetic potential, which is attributed to its ability to inhibit &#x003b1;-glucosidase and &#x003b1;- amylase [<xref rid="B70-plants-09-01784" ref-type="bibr">70</xref>]. Scientific evidence reports that naringenin administration results in the decline of blood glucose levels in streptozotocin-induced diabetic rats [<xref rid="B12-plants-09-01784" ref-type="bibr">12</xref>,<xref rid="B71-plants-09-01784" ref-type="bibr">71</xref>], develops insulin sensitivity in insulin-resistant rats that were given fructose [<xref rid="B72-plants-09-01784" ref-type="bibr">72</xref>], and diminishes resistance to insulin in mice consuming high-fat diets that lacked LDL receptors [<xref rid="B73-plants-09-01784" ref-type="bibr">73</xref>]. The mechanism of action of naringenin in type 2 diabetics is comparable to that of conventional antidiabetic metformin [<xref rid="B74-plants-09-01784" ref-type="bibr">74</xref>].</p><p>The adipose tissues of diabetic and obese people have exhibited a rich expression of numerous TLR family members [<xref rid="B75-plants-09-01784" ref-type="bibr">75</xref>]. Activation of TLR2 and TLR4 receptors by free fatty acids (FFA) ends up as insulin resistance [<xref rid="B76-plants-09-01784" ref-type="bibr">76</xref>,<xref rid="B77-plants-09-01784" ref-type="bibr">77</xref>]. Naringenin inhibits TLR2 expression in adipocytes through activation of peroxisome proliferator-activated receptor-gamma (PPAR&#x003b3;) [<xref rid="B78-plants-09-01784" ref-type="bibr">78</xref>]. It also downregulates TNF-&#x003b1;-induced TLR2 expression by decreasing NF-&#x003ba;B and c-Jun NH2-terminal kinase (JNK) pathways in differentiated adipocytes. Further pathology behind the advancement of insulin resistance and diabetes mellitus is the interaction of adipocytes and macrophages in the adipose tissue, which results in the inflammation of adipose tissue. Naringenin counteracts this inflammation by suppression of monocyte chemoattractant protein-1 (MCP-1) and migration of macrophages into adipose tissue [<xref rid="B79-plants-09-01784" ref-type="bibr">79</xref>]. Of all biomolecules, lipids have an inevitable role in the pathogenesis of diabetes mellitus [<xref rid="B80-plants-09-01784" ref-type="bibr">80</xref>]. A common metabolic anomaly related to diabetes mellitus is dyslipidemia. Research findings have reported various abnormalities in lipid metabolism attended by the risk of cardiovascular arteriosclerosis in DM patients [<xref rid="B81-plants-09-01784" ref-type="bibr">81</xref>]. Naringenin has been reported to have insulin-like effects, according to in vitro studies, which increase the expression of LDL receptor via PI3K-mediated upregulation of SREBP-1 in the cytosol and nucleus of human HepG2 and rat McA-RH7777 hepatoma cells. Naringenin treatment escalates the PI3K activity and reduces insulin receptor substrate-2 (IRS-2) levels. The plausible mechanism for naringenin&#x02019;s insulin-like effects is probably the increased activity of PI3K [<xref rid="B82-plants-09-01784" ref-type="bibr">82</xref>].</p><p>Diabetic neuropathic pain is one of the chief complications associated with diabetes mellitus [<xref rid="B83-plants-09-01784" ref-type="bibr">83</xref>]. Afflicted individuals often have complaints of &#x0201c;shock-like ambiances&#x0201d; with amplified sensations to external stimuli. This can have harmful and disabling effects [<xref rid="B84-plants-09-01784" ref-type="bibr">84</xref>,<xref rid="B85-plants-09-01784" ref-type="bibr">85</xref>]. Naringenin-treated Wistar rats have shown reduced pain and allodynic effects of diabetic neuropathy induced by streptozotocin [<xref rid="B86-plants-09-01784" ref-type="bibr">86</xref>]. Naringenin has also exhibited analgesic effects in an experimental model of neuropathic pain [<xref rid="B87-plants-09-01784" ref-type="bibr">87</xref>]. The possible mechanism behind the beneficial effects of naringenin may be the trigger of PPAR&#x003b3; [<xref rid="B88-plants-09-01784" ref-type="bibr">88</xref>]. Several studies have revealed that naringenin exhibits agonistic activity at the PPAR&#x003b3; receptor and therefore ameliorates the pain in different nerve injuries and neuropathies [<xref rid="B76-plants-09-01784" ref-type="bibr">76</xref>]. Moreover, naringenin has been reported to cause inhibition of nitric oxide (NO) pathway via downregulation of nitric oxide synthase (NOS), which is the main enzyme for NO synthesis [<xref rid="B89-plants-09-01784" ref-type="bibr">89</xref>] and a neurotransmitter for nociception [<xref rid="B90-plants-09-01784" ref-type="bibr">90</xref>]. The anti-diabetic mode of action of naringenin is diagrammatically represented in <xref ref-type="fig" rid="plants-09-01784-f004">Figure 4</xref>.</p></sec><sec id="sec3dot3-plants-09-01784"><title>3.3. Hepatoprotective Action</title><p>The liver is a primary organ in the metabolism and detoxification of drugs or chemical entities; therefore, it is highly prone to being negatively affected. The increased exposure to drugs, viruses, and toxins triggers severe liver damage and intensifies the probability of chronic liver disease [<xref rid="B91-plants-09-01784" ref-type="bibr">91</xref>,<xref rid="B92-plants-09-01784" ref-type="bibr">92</xref>]. Production of reactive oxygen species (ROS) may be the primary reason behind hepatotoxicity that can lead to various liver diseases. ROS induces peroxidation of cell membranes and prompts cell damage that culminates in leaching of enzymes like aspartate transaminase (AST) and alanine transaminase (ALT) [<xref rid="B93-plants-09-01784" ref-type="bibr">93</xref>]. Free radicals are also believed to be involved in the activation of caspase-3, -8, and -9, leading to the induction of apoptosis during hepatic impairment [<xref rid="B94-plants-09-01784" ref-type="bibr">94</xref>,<xref rid="B95-plants-09-01784" ref-type="bibr">95</xref>].</p><p>Various research groups have reported the hepatoprotective potential of naringenin [<xref rid="B11-plants-09-01784" ref-type="bibr">11</xref>,<xref rid="B96-plants-09-01784" ref-type="bibr">96</xref>,<xref rid="B97-plants-09-01784" ref-type="bibr">97</xref>,<xref rid="B98-plants-09-01784" ref-type="bibr">98</xref>,<xref rid="B99-plants-09-01784" ref-type="bibr">99</xref>,<xref rid="B100-plants-09-01784" ref-type="bibr">100</xref>,<xref rid="B101-plants-09-01784" ref-type="bibr">101</xref>], which is attributed to its potential in neutralizing the ROS via increased expression and activation of antioxidant enzymes [<xref rid="B102-plants-09-01784" ref-type="bibr">102</xref>,<xref rid="B103-plants-09-01784" ref-type="bibr">103</xref>] and the ability to amend gamma-glutamylcysteine synthetase (GGT) enzyme activity, which is involved in the GSH synthesis pathway [<xref rid="B104-plants-09-01784" ref-type="bibr">104</xref>,<xref rid="B105-plants-09-01784" ref-type="bibr">105</xref>,<xref rid="B106-plants-09-01784" ref-type="bibr">106</xref>]. Reportedly, pre-treatment with naringenin causes a decline in levels of AST and ALT, while antioxidant parameters, viz GPx, SOD, CAT, and GSH, have shown a significant increase [<xref rid="B101-plants-09-01784" ref-type="bibr">101</xref>,<xref rid="B107-plants-09-01784" ref-type="bibr">107</xref>]. The groups of rats intoxicated with CCl4 have shown repression of caspase-3 and -9 levels [<xref rid="B108-plants-09-01784" ref-type="bibr">108</xref>]. In a recently published article by Wu et al., the hepatoprotective action of naringenin has been attributed to its potential in inhibiting hepatic oxidative stress and inflammation [<xref rid="B109-plants-09-01784" ref-type="bibr">109</xref>].</p><p>Intake of drugs and production of metabolic toxins in the body can pave the way for the production and release of ROS [<xref rid="B38-plants-09-01784" ref-type="bibr">38</xref>], cytokines, and other inflammatory factors. This activates the Kupffer cells within the liver, thereby resulting in the destruction of hepatocytes [<xref rid="B110-plants-09-01784" ref-type="bibr">110</xref>,<xref rid="B111-plants-09-01784" ref-type="bibr">111</xref>,<xref rid="B112-plants-09-01784" ref-type="bibr">112</xref>]. Hepatic stellate cells (HSCs), which play a role in the formation of basement membranes by producing small amounts of extracellular matrix components like collagen type IV and laminin, when exposed to factors released from the stimulated Kupffer cells, lose their lipid level and then go through phenotypic alterations, proliferate, and produce excess amounts of extracellular matrix, thus resulting in liver fibrosis [<xref rid="B8-plants-09-01784" ref-type="bibr">8</xref>,<xref rid="B113-plants-09-01784" ref-type="bibr">113</xref>,<xref rid="B114-plants-09-01784" ref-type="bibr">114</xref>]. Naringenin has shown hepatoprotective and anti-fibrotic effects against dimethylnitrosamine (DMN)-mediated liver injury in rats, while oral consumption of naringenin has resulted in reduction of AST, ALT, and ALP and bilirubin levels. Furthermore, staining of liver tissue sections with Sirius red stain has revealed a reduction in collagen accumulation in the naringenin-treated rats. Naringenin has also been reported to reduce the activation of hepatic stellate cells [<xref rid="B103-plants-09-01784" ref-type="bibr">103</xref>]. The effect of naringenin on inflammatory changes in the liver triggered by high dietary cholesterol has been extensively studied and has been found to significantly decrease the release of pro-inflammatory mediators and downregulate the expression of TNF-&#x003b1; and MMP-2 and MMP-9, which contributes to reduced macrophage infiltration [<xref rid="B115-plants-09-01784" ref-type="bibr">115</xref>,<xref rid="B116-plants-09-01784" ref-type="bibr">116</xref>]. It also modulates the levels of necrotic inflammation by degrading extracellular matrix [<xref rid="B117-plants-09-01784" ref-type="bibr">117</xref>,<xref rid="B118-plants-09-01784" ref-type="bibr">118</xref>,<xref rid="B119-plants-09-01784" ref-type="bibr">119</xref>]. Additionally, naringenin has been shown to alleviate inflammation induced by hyperglycemia in streptozotocin-nicotinamide-induced diabetes mellitus in rats [<xref rid="B117-plants-09-01784" ref-type="bibr">117</xref>].</p></sec><sec id="sec3dot4-plants-09-01784"><title>3.4. Neuroprotective Action</title><p>In comparison to other body tissues, nerve cells are extremely sensitive to oxidative insults for the following reasons. (1) Brain cells are enriched in metal ions and polyunsaturated fatty acids. With the progression of time and age, the metal ions are accumulated in the brain, thus facilitating the formation of oxidative species. On the other hand, polyunsaturated fatty acids are more liable to oxidation and therefore may be responsible for oxidative stress. (2) In comparison to other cells, neuronal cells highly rely on oxidative phosphorylation for their main source of energy. (3) There is a lack of defense mechanisms operating in brain because it contains very meager quantities of antioxidant enzymes. These factors provide distinct evidence that the oversensitivity of nerve cells towards the stress is initiated and instigated by ROS [<xref rid="B118-plants-09-01784" ref-type="bibr">118</xref>].</p><p>It is a well-established fact that oxidative stress is substantially enhanced during the aging process, which may play an important role in increasing the vulnerability of neuronal systems to neurodegenerative diseases such as Parkinson&#x02019;s and Alzheimer&#x02019;s [<xref rid="B119-plants-09-01784" ref-type="bibr">119</xref>]. For the past ten decades, a 6-OHDA induced model of substantia nigra damage has established its identity as a classical model for the study of Parkinsonism in lab animals [<xref rid="B120-plants-09-01784" ref-type="bibr">120</xref>]. It is known to produce changes similar to the pathological features of Parkinson&#x02019;s disease (PD). The lesion induced by 6-OHDA in the nigrostriatal pathway leads to continuous depletion of dopaminergic neurons in the substantia nigra pars compacta (SNpc) thus increasing oxidative stress [<xref rid="B121-plants-09-01784" ref-type="bibr">121</xref>]. Naringenin is thought to have high permeability towards blood-brain barrier (BBB) as per various in vitro and in situ studies [<xref rid="B122-plants-09-01784" ref-type="bibr">122</xref>,<xref rid="B123-plants-09-01784" ref-type="bibr">123</xref>]. Pre-treatment of rats with naringenin has exhibited significant neuroprotection against 6-OHDA-induced toxicity [<xref rid="B124-plants-09-01784" ref-type="bibr">124</xref>]. The evidence in favor of neuroprotection is supported by the affinity of naringenin towards the striatum and cerebral cortex [<xref rid="B121-plants-09-01784" ref-type="bibr">121</xref>]. The rotenone-induced PD model has also reported promising results in the administration of naringenin, with significant restoration of motor skills, body weight, expression of parkin, DJ-1, tyrosine hydroxylase, and chromatin immunoprecipitation (ChIP) in the striatum and substantia nigra [<xref rid="B125-plants-09-01784" ref-type="bibr">125</xref>]. Among the disorders of CNS, Alzheimer&#x02019;s disease holds the maximum potential of negatively affecting the capability of learning and memory. It is usually characterized by amplified institution of beta-amyloid (A&#x003b2;) plaques. Alterations induced due to age in monoaminergic neurotransmitters (serotonin, noradrenaline, and dopamine) with an increase in tryptophan hydroxylase and tyrosine hydroxylase activity have also been reported. The Alzheimer rat model replicated by A&#x003b2;-injection has revealed improvement in cognitive functions through alleviation of lipid peroxidation and apoptosis on treatment with naringenin [<xref rid="B80-plants-09-01784" ref-type="bibr">80</xref>]. Studies reveal that naringenin could prove helpful in reversing the cognitive loss associated with AD by upregulating insulin signaling in the rat brain [<xref rid="B126-plants-09-01784" ref-type="bibr">126</xref>,<xref rid="B127-plants-09-01784" ref-type="bibr">127</xref>].</p><p>Covalent combination of naringenin with lipoic acid results in the generation of a novel compound, namely &#x0201c;VANL-100&#x0201d;. The in vitro and in vivo models of ischemia/reperfusion have exhibited neuroprotection at very low concentrations of 2 &#x000d7; 10<sup>&#x02212;2</sup> &#x000b5;M (100-fold more potent). The reason could be the increased capability of nerve cells in the presence of &#x0201c;VANL-100&#x0201d; to hunt down free radicals [<xref rid="B9-plants-09-01784" ref-type="bibr">9</xref>]. Naringenin was found to be effective in the management of cerebral ischemia by reducing oxidative injuries and NF-&#x003ba;B-mediated inflammation [<xref rid="B128-plants-09-01784" ref-type="bibr">128</xref>]. In another study, it was reported that naringenin has protective effects in experimental ischemic stroke models with improvement in neurological insufficiency and brain swelling with a reduction in infarct size [<xref rid="B129-plants-09-01784" ref-type="bibr">129</xref>].</p><p>The increase in the concentration of free radicals in neuronal cells may inhibit Acetylcholinesterase (AChE) activity. Rats exposed to iron have exhibited diminution in AChE levels, whereas naringenin administration to iron-exposed rats revealed a significant restoration in AChE activity due to its effective antioxidant potential [<xref rid="B130-plants-09-01784" ref-type="bibr">130</xref>]. In addition, naringenin supplementation exhibits the restoration of expression of acetyl choline transferase, resulting in the amendment of learning and memory in the treated models [<xref rid="B131-plants-09-01784" ref-type="bibr">131</xref>]. Improvement in cholinergic and serotonergic transmission upon treatment with naringenin has also been reported [<xref rid="B132-plants-09-01784" ref-type="bibr">132</xref>]. Naringenin also has the potential to protect the integrity of cells by controlling the antioxidant defense systems&#x02014;both enzymatic as well as non-enzymatic ones. Therefore, naringenin can have modulatory effects on neuronal cholinergic neurotransmission resting membrane potential, directly or indirectly [<xref rid="B116-plants-09-01784" ref-type="bibr">116</xref>].</p><p>The capability of naringenin to alter glucose homeostasis in the brain has been recently studied. This can pave the way for a better understanding of insulin-dependent and -independent mechanisms involved in experimental diabetes. Pre-treatment with naringenin in epileptic mice has revealed its anti-epileptic potential as it curbs different oxidative stress biomarkers with the improvement in behavioral parameters [<xref rid="B4-plants-09-01784" ref-type="bibr">4</xref>].</p></sec><sec id="sec3dot5-plants-09-01784"><title>3.5. Cardioprotective Action</title><p>Free radicals and reactive oxygen species (ROSs) are byproducts of the basal aerobic metabolism of cells. However, excessive generation of ROSs does result in critical oxidative damage to the cellular components of the cells [<xref rid="B133-plants-09-01784" ref-type="bibr">133</xref>,<xref rid="B134-plants-09-01784" ref-type="bibr">134</xref>]. Numerous studies suggest that naringenin exhibits profound antioxidant effects against various oxidative insults, which has been reported to improve cardiac functionality even after injuries [<xref rid="B135-plants-09-01784" ref-type="bibr">135</xref>]. The preclinical and clinical evidence in favor of this has been supported by the findings of various research groups [<xref rid="B92-plants-09-01784" ref-type="bibr">92</xref>]. One such study conducted by a team of researchers from Cairo University, Egypt, reported that there was a restoration in various antioxidant enzymes including superoxide dismutase (SOD), glutathione-S-transferase (GST), and catalase (CAT) on pre-treatment with naringenin against doxorubicin-induced cardiotoxicity in male Swiss albino rats [<xref rid="B136-plants-09-01784" ref-type="bibr">136</xref>]. In this context, Han et al. (2008) later studied the pathway utilized by naringenin to protect cardiomyocytes from doxorubicin-induced cardiac toxicity [<xref rid="B137-plants-09-01784" ref-type="bibr">137</xref>] and found that the upregulation of several endogenous enzymes possessing antioxidant activities via extracellular regulated kinase 1/2 (ERK1/2) phosphorylation and Nrf2 activation and translocation into the nucleus likely had a key role in the protection of cardiomyocytes. The findings indicated that naringenin protects against cardiomyocyte apoptosis by expressing higher endogenous antioxidants enzyme (SOD, GST, and CAT) via phosphorylation of ERK1/2 and nuclear translocation of Nrf2 [<xref rid="B137-plants-09-01784" ref-type="bibr">137</xref>]. Subsequently, other researchers opened the horizons of its mechanism and noted that naringenin suppresses the generation of reactive species [<xref rid="B45-plants-09-01784" ref-type="bibr">45</xref>], increases the activities of antioxidant enzymes such as superoxide dismutase (SOD) and catalases, and reduces the phosphorylation of ERK1/2 and p38 MAPK. Moreover, it prevents the binding of angiotensin II to angiotensin binding receptors AT1 receptor and AT2 receptor, thereby suppressing the vascular smooth muscle cell proliferation [<xref rid="B138-plants-09-01784" ref-type="bibr">138</xref>].</p><p>Naringenin exhibited its cardioprotective effect by reducing myocardial infarct area, decreasing LDH in coronary effluent to increase regenerative capacity, and improving the retrieval of left ventricular function. Naringenin-treated myocardium has also exhibited an increase in SOD and a decrease in levels of MDA [<xref rid="B139-plants-09-01784" ref-type="bibr">139</xref>]. The useful outcomes of naringenin on the heart can be related to its potential to act on calcium-activated potassium channels. Naringenin restricts the build-up of calcium in the cardiac mitochondrial matrix. An amendment of functional parameters post-ischemia with a lowering of the lengthening interval of myocardial injury has also been observed. The inner mitochondrial membrane depolarization depends on the concentration of thallium, and the transmembrane drift of thallium (potassium-mimetic cation) has been reported in isolated rat cardiac mitochondria upon interaction with naringenin [<xref rid="B140-plants-09-01784" ref-type="bibr">140</xref>].</p><p>Pink grapefruit is a hybrid citrus fruit produced by cross-hybridization of sweet orange (<italic>Clonorchis sinensis</italic>) and pomelo (<italic>Cucurbita maxima</italic>). It is known to be rich in naringenin. It increases temporal cardiac repolarization dispersion and therefore prolongs repolarization. In patients with structural disorders of the myocardium, it may be of value because of its pro-arrhythmic actions [<xref rid="B141-plants-09-01784" ref-type="bibr">141</xref>]. In pressure over-loaded mice, treatment with naringenin improved left cardiac hypertrophy and interstitial fibrosis. Amendment of left ventricular functions has also been reported. The action mechanism is thought to be via inhibition of ERK, PI3K/Akt, and JNK signaling pathways [<xref rid="B142-plants-09-01784" ref-type="bibr">142</xref>]. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) is one of the key ROSs, produced endogenously in the respiratory cascade of mitochondria and as a byproduct of basal metabolism. There are several other organs, such as the endoplasmic reticulum and peroxisome, that are thought to be its primary site of production. Due to its potent oxidative property, H<sub>2</sub>O<sub>2</sub> induces severe detrimental effects on cardiomyoblasts, which may be reversed by naringenin treatments. Synthesis of antioxidant enzymes (CAT, SOD, and nitric oxide) decreases stress-facilitated apoptosis and lipid peroxidation with subsequent increase GSH levels. Naringenin has also shown upregulation in the transcription of Akt and Nrf2 coupled with downregulation of Caspase-3 and NF-&#x003ba;B genes. It also prevents apoptosis in H9c2 cardiac myocytes through inactivation of caspase-3, -8, and -9 and decreases the expressions of apoptosis (mitochondrial pathway) regulating proteins of Bcl-2 such as Bax and Bak [<xref rid="B143-plants-09-01784" ref-type="bibr">143</xref>,<xref rid="B144-plants-09-01784" ref-type="bibr">144</xref>].</p><p>Furthermore, naringenin administration in HCD rats exhibits significant improvements in serum levels of nitric oxide, LDH, oxidative damage markers of lipids, and lipid profile [<xref rid="B119-plants-09-01784" ref-type="bibr">119</xref>]. Naringenin was found to reduce the chances of atherosclerosis by alleviating dyslipidemia and insulin resistance, thereby inhibiting the assembly of apolipoprotein B100. Studies have also shown that naringenin increases fatty acid oxidation and blocks cholesterol synthesis and esterification, which results in reduced hepatic triglycerides and decreases cholesteryl ester; thus, there is a limited secretion of VLDL [<xref rid="B145-plants-09-01784" ref-type="bibr">145</xref>].</p></sec><sec id="sec3dot6-plants-09-01784"><title>3.6. Nephroprotective Action</title><p>As per a WHO report, about 35 million people are suffering from chronic kidney diseases (CKD) in developing and developed countries. Inflammatory cytokines and oxidative stress play a pivotal role in the progression of renal damage. The specific targets for renal injury are the mesangial cells, glomerular endothelial cells, podocytes, and tubular epithelial cells [<xref rid="B146-plants-09-01784" ref-type="bibr">146</xref>]. Other forms of kidney damage are reported to be induced by renin&#x02013;angiotensin system (RAS) activation or Angiotensin II type I receptor (AT1R) and endothelin receptors [<xref rid="B19-plants-09-01784" ref-type="bibr">19</xref>], i.e., ET receptor type A and type B [<xref rid="B147-plants-09-01784" ref-type="bibr">147</xref>,<xref rid="B148-plants-09-01784" ref-type="bibr">148</xref>]. The activation of these receptors contributes to nephrotoxicity by increasing microvascular pressure and/or destruction of podocytes. Activation of these receptors leads to kidney damage by increasing microvascular pressure, podocyte autophagy, promoting oxidative stress and NF&#x003ba;B-p65 activation; which in turn trigger the release of inflammatory mediators like IFN&#x003b3;, IL-6, and prostaglandins [<xref rid="B149-plants-09-01784" ref-type="bibr">149</xref>]. Ameliorative effect of naringenin in different drug-induced nephrotoxicity models has been reported. The Western blotting technique of protein analysis in rats suffering from daunorubicin-induced kidney damage has revealed upregulation of PPAR&#x003b3; and attenuation of AT1R, ETAR, p-NF&#x003ba;B p65, and p-ERK1/2 signaling pathways, thereby reducing oxidative stress and inflammation following naringenin treatment. Histopathological analysis of the kidney has also shown improvement in fibrotic lesions in a naringenin-administered group [<xref rid="B150-plants-09-01784" ref-type="bibr">150</xref>].</p><p>Additionally, involvement of peroxisome proliferator-activated receptors PPAR&#x003b3; in NF-kB and MAPK signaling in drug-induced renal toxicity in a rodent model has been reported [<xref rid="B151-plants-09-01784" ref-type="bibr">151</xref>]. Moreover, a marked reduction in levels of interleukin-8, serum creatinine level, and nitric oxide [<xref rid="B22-plants-09-01784" ref-type="bibr">22</xref>] level and reduced GPx activity after naringenin administration in gentamicin-treated rats have been reported [<xref rid="B152-plants-09-01784" ref-type="bibr">152</xref>]. Drug-induced nephrotoxicity is associated with the release of kidney injury molecule-1 (KIM-1) and IL-8, which are the kidney damage biomarkers. KIM-1, a glycoprotein, acts as a receptor for phosphatidylserine present on the cells undergoing apoptosis for phagocytosis [<xref rid="B153-plants-09-01784" ref-type="bibr">153</xref>], while IL-8 is an endothelial-derived cytokine responsible for oxidative burst and chemotaxis of neutrophils at the site of inflammation or injury. Immunohistochemical examinations of naringenin-treated tissues have shown significant downregulation of different biomarkers, including VEGF, iNOS, and caspase-9; in contrast, there is enhanced expression of survivin in the renal tissue [<xref rid="B152-plants-09-01784" ref-type="bibr">152</xref>]. Survivin is an anti-apoptotic factor that suppresses apoptosis by either inhibiting activation of caspase-9 [<xref rid="B154-plants-09-01784" ref-type="bibr">154</xref>] or by preventing cytochrome-c release via inhibition of Fas/Fas ligand stimulation [<xref rid="B151-plants-09-01784" ref-type="bibr">151</xref>]. Naringenin has also shown protective action against cisplatin-induced renal toxicity in a rat model [<xref rid="B155-plants-09-01784" ref-type="bibr">155</xref>], cadmium-mediated oxidative kidney impairment [<xref rid="B98-plants-09-01784" ref-type="bibr">98</xref>], and acute renal toxicity induced by carbon tetrachloride [<xref rid="B96-plants-09-01784" ref-type="bibr">96</xref>].</p></sec><sec id="sec3dot7-plants-09-01784"><title>3.7. Gastroprotective Action</title><p>Because of the highly permeable nature of naringenin, it is absorbed throughout the gastrointestinal tract, largely in the small intestine via passive diffusion [<xref rid="B156-plants-09-01784" ref-type="bibr">156</xref>]. The gastroprotective effect of naringenin may be attributed to its anti-inflammatory activities, which is primarily achieved through inhibition of activator protein-1 and NF-&#x003ba;B signaling and activation of P38 MAPK and ERK 5 [<xref rid="B157-plants-09-01784" ref-type="bibr">157</xref>]. Over time, IBDs are known to progress to more severe forms like ulcerative colitis [<xref rid="B156-plants-09-01784" ref-type="bibr">156</xref>] and Crohn&#x02019;s disease (CD). In such cases, treatment with naringenin has revealed anti-ulcerogenic effects in the form of decline in tissue ulceration, inflammation, and necrosis of the colon [<xref rid="B158-plants-09-01784" ref-type="bibr">158</xref>]. In addition, beneficial effects of naringenin may also be accomplished through suppression of pro-inflammatory markers like iNOS, reduction of inflammatory cytokines, diminished TLR4 mRNA, and protein concentration in mucosa [<xref rid="B159-plants-09-01784" ref-type="bibr">159</xref>].</p><p>Naringenin is activated by interaction with serotonin (5-HT4) receptor antagonists, which in turn increase the colonic contractions, enabling the process of gastric emptying [<xref rid="B160-plants-09-01784" ref-type="bibr">160</xref>]. Certain endogenous molecules like Motilin and Ghrelin released from the stomach, small intestines, and pancreas stimulate GI motility through their action on distinctive receptors [<xref rid="B161-plants-09-01784" ref-type="bibr">161</xref>]. Naringenin has been reported to function as an agonist to Ghrelin receptors, thereby improving various GI disturbances [<xref rid="B162-plants-09-01784" ref-type="bibr">162</xref>]. In SGC-7901 cell lines, naringenin exhibited induction of apoptosis along with suppression of proliferation, migration, and invasion. The possible reason may be the inhibition of AKT phosphorylation and decline in expression of target molecules by naringenin [<xref rid="B163-plants-09-01784" ref-type="bibr">163</xref>]. Zhang et al. have reported that naringenin suppressed the growth of stomach cancer cells in SGC-7901 cell lines [<xref rid="B164-plants-09-01784" ref-type="bibr">164</xref>].</p></sec><sec id="sec3dot8-plants-09-01784"><title>3.8. Role of Naringenin in Pulmonary Diseases</title><p>Lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and pulmonary fibrosis are chronic airway inflammatory diseases (CAID) characterized by inflammatory response by the respiratory tract against certain external agents, including pathogens, smoke, and dust particles, resulting in increased production of inflammatory cells, mucous production, and inflammatory mediators causing impaired lung function. The inflammatory response in CAID is believed to be mediated by numerous inflammatory factors such as inflammatory cytokines, interleukins, glucocorticoid receptors, tumor necrosis factors (TNF-a), and nuclear factor kappa B (NF-kB). These inflammatory factors result in elevated oxidative stress, which stimulates immune responses, promotes hyper-responsiveness of the bronchi, and increases the secretion of mucin [<xref rid="B165-plants-09-01784" ref-type="bibr">165</xref>].</p><p>It has been reported that naringenin inhibits the inflammatory pathway involved in CAID by inhibiting NF-kB transcription activity [<xref rid="B166-plants-09-01784" ref-type="bibr">166</xref>]. Further, naringenin inhibits the inflammatory response in the respiratory tract initiated by microbial products involving pro-inflammatory cytokines, IL-1, NF-kB, and TNF-a. Naringenin inhibits the degradation of IkB that is bound to the p50/p65 subunit of NF-kB and thereby inhibits NF-kB activity [<xref rid="B165-plants-09-01784" ref-type="bibr">165</xref>,<xref rid="B167-plants-09-01784" ref-type="bibr">167</xref>]. Furthermore, numerous in vivo studies have shown the therapeutic effect of naringenin in airway inflammatory diseases [<xref rid="B165-plants-09-01784" ref-type="bibr">165</xref>].</p></sec><sec id="sec3dot9-plants-09-01784"><title>3.9. Antimicrobial Action</title><p>Presently, natural products have drawn attention because of their potent antimicrobial activities and fewer side effects than chemically synthesized compounds. Natural products are considered safe and are advantageous over antibiotics because of the lesser chances of drug resistance associated with them. It is less likely for bacterial strains to develop resistance against a compound of natural origin because of their multiple mechanisms of action on bacterial cells. Natural products exert their antibacterial activity by interaction with the bacterial membrane and disruption of its integrity, inhibition of enzymes necessary for bacterial membrane synthesis, anti-biofilm activity, or inhibition of auto inducer-mediated cell&#x02013;cell signaling [<xref rid="B168-plants-09-01784" ref-type="bibr">168</xref>].</p><p>Naringenin possesses a wide spectrum of antimicrobial activities, including antifungal and antibacterial [<xref rid="B169-plants-09-01784" ref-type="bibr">169</xref>]. Naringenin is found to possess potent activity against Methicillin-resistant <italic>Staphylococcus aureus</italic> [<xref rid="B170-plants-09-01784" ref-type="bibr">170</xref>] and resistant strains of <italic>Helicobacter pylori</italic> [<xref rid="B171-plants-09-01784" ref-type="bibr">171</xref>]. Naringenin exhibits its antibacterial action by inhibiting the autoinducer-mediated cell signaling pathway [<xref rid="B172-plants-09-01784" ref-type="bibr">172</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec4-plants-09-01784"><title>4. Conclusions and Future Perspective</title><p>In the present review, we have presented broad pharmacological aspects of naringenin reflected from the latest research. Evidence from collected literature has revealed that naringenin has several notable pharmacological properties, e.g., antioxidant, anti-inflammatory, antimicrobial, anti-diabetic, and anticancer. There are many molecular mechanisms fundamental to the pleotropic activities of naringenin, which involve the amalgamation of cellular signaling pathways at numerous levels of different diseases. Despite its tremendous potential in augmenting different diseases, naringenin is limited by a bioavailability problem, like other polyphenols. Methods to enhance the bioavailability of naringenin must be investigated to enhance the efficiency of naringenin as a therapeutic. Further active research is warranted to discover the promising therapeutic potentials of naringenin with respect to the promotion of better human health. Parallel research is also needed to enhance its bioavailability, which is instrumental in exerting the effective pharmacological effects of naringenin.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through Research Group Number (RG-1441-397).</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.A. (Azher Arafah) and M.U.R., A.F.W.; Methodology, A.A. (Azher Arafah), M.U.R., R.A., W.Q., R.K.; Formal Analysis, M.U.R., A.F.W., R.A., and S.S.A.; Resources, A.A. (Ajaz Ahmad), S.A., N.M.A., and S.S.A.; Writing&#x02014;Original Draft Preparation, M.U.R., R.A., W.Q., R.K., T.M.M.; Writing&#x02014;Review and Editing, M.U.R., S.A., S.S.A., N.M.A.; Project Administration, A.A. (Azher Arafah), M.U.R., and S.S.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was funded by [King Saud University] grant number [RG-1441-397].</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declared no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-plants-09-01784"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panche</surname><given-names>A.N.</given-names></name><name><surname>Diwan</surname><given-names>A.D.</given-names></name><name><surname>Chandra</surname><given-names>S.R.</given-names></name></person-group><article-title>Flavonoids: An overview</article-title><source>J. Nutr. Sci.</source><year>2016</year><volume>5</volume><fpage>e47</fpage><pub-id pub-id-type="doi">10.1017/jns.2016.41</pub-id><?supplied-pmid 28620474?><pub-id pub-id-type="pmid">28620474</pub-id></element-citation></ref><ref id="B2-plants-09-01784"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tungmunnithum</surname><given-names>D.</given-names></name><name><surname>Thongboonyou</surname><given-names>A.</given-names></name><name><surname>Pholboon</surname><given-names>A.</given-names></name><name><surname>Yangsabai</surname><given-names>A.</given-names></name></person-group><article-title>Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview</article-title><source>Medicines</source><year>2018</year><volume>5</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.3390/medicines5030093</pub-id><?supplied-pmid 30149600?><pub-id pub-id-type="pmid">30149600</pub-id></element-citation></ref><ref id="B3-plants-09-01784"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuelsen</surname><given-names>A.B.</given-names></name></person-group><article-title>The traditional uses, chemical constituents and biological activities of <italic>Plantago major</italic> L. A review</article-title><source>J. Ethnopharmacol.</source><year>2000</year><volume>71</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(00)00212-9</pub-id><pub-id pub-id-type="pmid">10904143</pub-id></element-citation></ref><ref id="B4-plants-09-01784"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>G.K.</given-names></name><name><surname>Patel</surname><given-names>D.K.</given-names></name></person-group><article-title>A Review on Pharmacological and Analytical Aspects of Naringenin</article-title><source>Chin. J. Integr. Med.</source><year>2014</year><volume>24</volume><fpage>551</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1007/s11655-014-1960-x</pub-id><?supplied-pmid 25501296?><pub-id pub-id-type="pmid">25501296</pub-id></element-citation></ref><ref id="B5-plants-09-01784"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rani</surname><given-names>N.</given-names></name><name><surname>Bharti</surname><given-names>S.</given-names></name><name><surname>Krishnamurthy</surname><given-names>B.</given-names></name><name><surname>Bhatia</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Kamal</surname><given-names>M.A.</given-names></name><name><surname>Ojha</surname><given-names>S.</given-names></name><name><surname>Arya</surname><given-names>D.S.</given-names></name></person-group><article-title>Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>4341</fpage><lpage>4359</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160530150936</pub-id><?supplied-pmid 27238365?><pub-id pub-id-type="pmid">27238365</pub-id></element-citation></ref><ref id="B6-plants-09-01784"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shakeel</surname><given-names>S.</given-names></name><name><surname>Rehman</surname><given-names>M.U.</given-names></name><name><surname>Tabassum</surname><given-names>N.</given-names></name><name><surname>Amin</surname><given-names>U.</given-names></name></person-group><article-title>Effect of naringenin (A naturally occurring flavanone) against pilocarpine-induced status epilepticus and oxidative stress in mice</article-title><source>Pharm. Mag.</source><year>2017</year><volume>13</volume><fpage>154</fpage><pub-id pub-id-type="doi">10.4103/0973-1296.203977</pub-id></element-citation></ref><ref id="B7-plants-09-01784"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mir</surname><given-names>I.A.</given-names></name><name><surname>Tiku</surname><given-names>A.B.</given-names></name></person-group><article-title>Chemopreventive and therapeutic potential of &#x0201c;naringenin,&#x0201d; a flavanone presents in citrus fruits</article-title><source>Nutr. Cancer</source><year>2015</year><volume>67</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/01635581.2015.976320</pub-id><pub-id pub-id-type="pmid">25514618</pub-id></element-citation></ref><ref id="B8-plants-09-01784"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>M.A.</given-names></name><name><surname>Subhan</surname><given-names>N.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Uddin</surname><given-names>S.J.</given-names></name><name><surname>Reza</surname><given-names>S.</given-names></name></person-group><article-title>Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action</article-title><source>Adv. Nutr.</source><year>2014</year><volume>5</volume><fpage>404</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.3945/an.113.005603</pub-id><pub-id pub-id-type="pmid">25022990</pub-id></element-citation></ref><ref id="B9-plants-09-01784"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidun</surname><given-names>N.H.</given-names></name><name><surname>Thent</surname><given-names>Z.C.</given-names></name><name><surname>Latiff</surname><given-names>A.A.</given-names></name></person-group><article-title>Combating oxidative stress disorders with citrus flavonoid: Naringenin</article-title><source>Life Sci.</source><year>2018</year><volume>208</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.07.017</pub-id><pub-id pub-id-type="pmid">30021118</pub-id></element-citation></ref><ref id="B10-plants-09-01784"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Fermentation and metabolic pathway optimization to de novo synthesize (2S)-naringenin in Escherichia coli</article-title><source>J. Microbiol. Biotechnol.</source><year>2020</year><pub-id pub-id-type="doi">10.4014/jmb.2008.08005</pub-id></element-citation></ref><ref id="B11-plants-09-01784"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>B.</given-names></name><name><surname>Fokou</surname><given-names>P.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>M.</given-names></name><name><surname>Zucca</surname><given-names>P.</given-names></name><name><surname>Pezzani</surname><given-names>R.</given-names></name><name><surname>Martins</surname><given-names>N.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name></person-group><article-title>The Therapeutic Potential of Naringenin: A Review of Clinical Trials</article-title><source>Pharmaceuticals</source><year>2019</year><volume>12</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/ph12010011</pub-id><?supplied-pmid 30634637?><pub-id pub-id-type="pmid">30634637</pub-id></element-citation></ref><ref id="B12-plants-09-01784"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Pandey</surname><given-names>A.K.</given-names></name></person-group><article-title>Chemistry and biological activities of flavonoids: An overview</article-title><source>Sci. World J.</source><year>2013</year><fpage>62750</fpage><pub-id pub-id-type="doi">10.1155/2013/162750</pub-id><?supplied-pmid 24470791?><pub-id pub-id-type="pmid">24470791</pub-id></element-citation></ref><ref id="B13-plants-09-01784"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Naringenin-loaded solid lipid nanoparticles: Preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics</article-title><source>Drug Des. Dev. Ther.</source><year>2016</year><volume>10</volume><fpage>911</fpage><pub-id pub-id-type="doi">10.2147/DDDT.S97738</pub-id></element-citation></ref><ref id="B14-plants-09-01784"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>T.M.</given-names></name><name><surname>Saleh</surname><given-names>M.C.</given-names></name><name><surname>Connell</surname><given-names>B.J.</given-names></name><name><surname>Song</surname><given-names>Y.H.</given-names></name></person-group><article-title>A co-drug conjugate of naringenin and lipoic acid mediates neuroprotection in a rat model of oxidative stress</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2017</year><volume>46</volume><fpage>1008</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12799</pub-id><?supplied-pmid 28636787?><pub-id pub-id-type="pmid">28636787</pub-id></element-citation></ref><ref id="B15-plants-09-01784"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>G.</given-names></name><name><surname>Sakurai</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study</article-title><source>Phytother. Res.</source><year>2013</year><volume>27</volume><fpage>1345</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1002/ptr.4867</pub-id><pub-id pub-id-type="pmid">23148023</pub-id></element-citation></ref><ref id="B16-plants-09-01784"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanaze</surname><given-names>F.I.</given-names></name><name><surname>Bounartzi</surname><given-names>M.I.</given-names></name><name><surname>Georgarakis</surname><given-names>M.</given-names></name><name><surname>Niopas</surname><given-names>I.</given-names></name></person-group><article-title>Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects</article-title><source>Eur. J. Clin. Nutr.</source><year>2007</year><volume>61</volume><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1602543</pub-id><pub-id pub-id-type="pmid">17047689</pub-id></element-citation></ref><ref id="B17-plants-09-01784"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>R.</given-names></name><name><surname>Kulkarni</surname><given-names>Y.A.</given-names></name><name><surname>Wairkar</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: An update</article-title><source>Life Sci.</source><year>2018</year><volume>215</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.10.066</pub-id><pub-id pub-id-type="pmid">30391464</pub-id></element-citation></ref><ref id="B18-plants-09-01784"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivoira</surname><given-names>M.A.</given-names></name><name><surname>Rodriguez</surname><given-names>V.</given-names></name><name><surname>Talamoni</surname><given-names>G.</given-names></name><name><surname>Tolosa de Talamoni</surname><given-names>N.</given-names></name></person-group><article-title>New Perspectives in the Pharmacological Potential of Naringin in Medicine</article-title><source>Curr. Med. Chem.</source><year>2020</year><pub-id pub-id-type="doi">10.2174/0929867327666200604171351</pub-id></element-citation></ref><ref id="B19-plants-09-01784"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Andrade</surname><given-names>R.</given-names></name><name><surname>S&#x000e1;nchez-Salgado</surname><given-names>J.</given-names></name><name><surname>Navarrete-V&#x000e1;zquez</surname><given-names>G.</given-names></name><name><surname>Webster</surname><given-names>S.</given-names></name><name><surname>Binnie</surname><given-names>M.</given-names></name><name><surname>Garc&#x000ed;a-Jim&#x000e9;nez</surname><given-names>S.</given-names></name><name><surname>Estrada-Soto</surname><given-names>S.</given-names></name></person-group><article-title>Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation</article-title><source>Diabetes Obes. Metab.</source><year>2008</year><volume>10</volume><fpage>1097</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2008.00869.x</pub-id><pub-id pub-id-type="pmid">18355329</pub-id></element-citation></ref><ref id="B20-plants-09-01784"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuhr</surname><given-names>U.</given-names></name><name><surname>Klittich</surname><given-names>K.</given-names></name><name><surname>Staib</surname><given-names>A.H.</given-names></name></person-group><article-title>Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man</article-title><source>Br. J. Clin. Pharmacol.</source><year>1994</year><volume>35</volume><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb04162.x</pub-id></element-citation></ref><ref id="B21-plants-09-01784"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuhr</surname><given-names>U.</given-names></name><name><surname>Kummert</surname><given-names>A.L.</given-names></name></person-group><article-title>The fate of naringin in humans: A key to grapefruit juice-drug interactions?</article-title><source>Clin. Pharmacol. Ther.</source><year>1995</year><volume>58</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/0009-9236(95)90048-9</pub-id><pub-id pub-id-type="pmid">7586927</pub-id></element-citation></ref><ref id="B22-plants-09-01784"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katavic</surname><given-names>P.L.</given-names></name><name><surname>Lamb</surname><given-names>K.</given-names></name><name><surname>Navarro</surname><given-names>H.</given-names></name><name><surname>Prisinzano</surname><given-names>T.E.</given-names></name></person-group><article-title>Flavonoids as Opioid Receptor Ligands: Identification and Preliminary Structure&#x02212; Activity Relationships</article-title><source>J. Nat. Prod.</source><year>2007</year><volume>70</volume><fpage>1278</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1021/np070194x</pub-id><?supplied-pmid 17685652?><pub-id pub-id-type="pmid">17685652</pub-id></element-citation></ref><ref id="B23-plants-09-01784"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renugadevi</surname><given-names>J.</given-names></name><name><surname>Prabu</surname><given-names>S.M.</given-names></name></person-group><article-title>Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin</article-title><source>Exp. Toxicol. Pathol.</source><year>2010</year><volume>62</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.etp.2009.03.010</pub-id><?supplied-pmid 19409769?><pub-id pub-id-type="pmid">19409769</pub-id></element-citation></ref><ref id="B24-plants-09-01784"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>A.</given-names></name><name><surname>Shetty</surname><given-names>T.</given-names></name><name><surname>Bhattacharya</surname><given-names>R.</given-names></name></person-group><article-title>Modulating effect of plant flavonoids on the mutagenicity of N-methyl- N&#x02032;-nitro-N-nitrosoguanidine</article-title><source>Carcinogenesis</source><year>1989</year><volume>10</volume><fpage>1953</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1093/carcin/10.10.1953</pub-id><?supplied-pmid 2676226?><pub-id pub-id-type="pmid">2676226</pub-id></element-citation></ref><ref id="B25-plants-09-01784"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekambaram</surname><given-names>G.</given-names></name><name><surname>Rajendran</surname><given-names>P.</given-names></name><name><surname>Magesh</surname><given-names>V.</given-names></name><name><surname>Sakthisekaran</surname><given-names>D.</given-names></name></person-group><article-title>Naringenin reduces tumor size and weight lost in N-methyl-N&#x02032;-nitro-N-nitrosoguanidine&#x02013;induced gastric carcinogenesis in rats</article-title><source>Nutr. Res.</source><year>2008</year><volume>28</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2007.12.002</pub-id><?supplied-pmid 19083396?><pub-id pub-id-type="pmid">19083396</pub-id></element-citation></ref><ref id="B26-plants-09-01784"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>K.F.R.</given-names></name><name><surname>Oliveira</surname><given-names>T.T.D.</given-names></name><name><surname>Nagem</surname><given-names>T.J.</given-names></name><name><surname>Pinto</surname><given-names>A.D.S.</given-names></name><name><surname>Oliveira</surname><given-names>M.G.</given-names></name></person-group><article-title>Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations</article-title><source>Pharm. Res.</source><year>1999</year><volume>40</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1006/phrs.1999.0556</pub-id></element-citation></ref><ref id="B27-plants-09-01784"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayidi</surname><given-names>S.</given-names></name><name><surname>Pari</surname><given-names>L.</given-names></name></person-group><article-title>Effect of naringenin on carbohydrate metabolism in streptozotocin-nicotinamide induced diabetic rats</article-title><source>Biomirror</source><year>2011</year><volume>2</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2008.00869.x</pub-id></element-citation></ref><ref id="B28-plants-09-01784"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldwasser</surname><given-names>J.</given-names></name><name><surname>Cohen</surname><given-names>P.Y.</given-names></name><name><surname>Yang</surname><given-names>E.</given-names></name><name><surname>Balaguer</surname><given-names>P.</given-names></name><name><surname>Yarmush</surname><given-names>M.L.</given-names></name><name><surname>Nahmias</surname><given-names>Y.</given-names></name></person-group><article-title>Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: Role of PPAR&#x003b1;, PPAR&#x003b3; and LXR&#x003b1;</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>12399</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012399</pub-id></element-citation></ref><ref id="B29-plants-09-01784"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollman</surname><given-names>P.C.H.</given-names></name><name><surname>Katan</surname><given-names>M.B.</given-names></name></person-group><article-title>Dietary flavonoids: Intake, health effects and bioavailability</article-title><source>Food Chem. Toxicol.</source><year>1999</year><volume>37</volume><fpage>937</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/S0278-6915(99)00079-4</pub-id><pub-id pub-id-type="pmid">10541448</pub-id></element-citation></ref><ref id="B30-plants-09-01784"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhakar</surname><given-names>A.</given-names></name></person-group><article-title>History of cancer, ancient and modern treatment methods</article-title><source>J. Cancer Sci. Ther.</source><year>2009</year><volume>1</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.4172/1948-5956.100000e2</pub-id><pub-id pub-id-type="pmid">20740081</pub-id></element-citation></ref><ref id="B31-plants-09-01784"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>F.</given-names></name><name><surname>Kabasakal</surname><given-names>B.V.</given-names></name><name><surname>Cotton</surname><given-names>C.</given-names></name><name><surname>Schumacher</surname><given-names>J.</given-names></name><name><surname>Rutherford</surname><given-names>A.W.</given-names></name><name><surname>Fantuzzi</surname><given-names>A.</given-names></name><name><surname>Murray</surname><given-names>J.W.</given-names></name></person-group><article-title>A low-potential terminal oxidase associated with the iron-only nitrogenase from the nitrogen-fixing bacterium Azotobacter vinelandii</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>9367</fpage><lpage>9376</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.007285</pub-id><?supplied-pmid 31043481?><pub-id pub-id-type="pmid">31043481</pub-id></element-citation></ref><ref id="B32-plants-09-01784"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friesen</surname><given-names>C.</given-names></name><name><surname>Herr</surname><given-names>I.</given-names></name><name><surname>Krammer</surname><given-names>P.H.</given-names></name><name><surname>Debatin</surname><given-names>K.M.</given-names></name></person-group><article-title>Involvement of the CD95 (APO&#x02013;1/Fas) receptor/ligand system in drug&#x02013;induced apoptosis in leukemia cells</article-title><source>Nat. Med.</source><year>1996</year><volume>2</volume><fpage>574</fpage><pub-id pub-id-type="doi">10.1038/nm0596-574</pub-id><?supplied-pmid 8616718?><pub-id pub-id-type="pmid">8616718</pub-id></element-citation></ref><ref id="B33-plants-09-01784"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durgo</surname><given-names>K.</given-names></name><name><surname>Koncar</surname><given-names>M.</given-names></name><name><surname>Komes</surname><given-names>D.</given-names></name><name><surname>Belscak-Cvitanovic</surname><given-names>A.</given-names></name><name><surname>Franekic</surname><given-names>J.</given-names></name><name><surname>Jakopovich</surname><given-names>I.</given-names></name><name><surname>Jakopovich</surname><given-names>B.</given-names></name></person-group><article-title>Cytotoxicity of blended versus single medicinal mushroom extracts on human cancer cell lines: Contribution of polyphenol and polysaccharide content</article-title><source>Int. J. Med. Mushrooms</source><year>2013</year><volume>15</volume><fpage>435</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1615/IntJMedMushr.v15.i5.20</pub-id><?supplied-pmid 24266369?><pub-id pub-id-type="pmid">24266369</pub-id></element-citation></ref><ref id="B34-plants-09-01784"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravishankar</surname><given-names>D.</given-names></name><name><surname>Rajora</surname><given-names>A.K.</given-names></name><name><surname>Greco</surname><given-names>F.</given-names></name><name><surname>Osborn</surname><given-names>H.M.</given-names></name></person-group><article-title>Flavonoids as prospective compounds for anti-cancer therapy</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2013</year><volume>45</volume><fpage>2821</fpage><lpage>2831</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.10.004</pub-id><pub-id pub-id-type="pmid">24128857</pub-id></element-citation></ref><ref id="B35-plants-09-01784"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefani</surname><given-names>E.D.</given-names></name><name><surname>Ronco</surname><given-names>A.</given-names></name><name><surname>Mendilaharsu</surname><given-names>M.</given-names></name><name><surname>Deneo-Pellegrini</surname><given-names>H.</given-names></name></person-group><article-title>Diet and risk of cancer of the upper aerodigestive tract&#x02014;II. Nutrients</article-title><source>Oral Oncol.</source><year>1999</year><volume>35</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S1368-8375(98)00061-X</pub-id><pub-id pub-id-type="pmid">10211306</pub-id></element-citation></ref><ref id="B36-plants-09-01784"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>P.</given-names></name><name><surname>Mishra</surname><given-names>N.D.</given-names></name></person-group><article-title>Role of flavonoids in DNA damage and carcinogenesis prevention</article-title><source>J. Carcinog. Mutagen.</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.4172/2157-2518.1000297</pub-id></element-citation></ref><ref id="B37-plants-09-01784"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>Y.J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Morris</surname><given-names>M.E.</given-names></name></person-group><article-title>Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism</article-title><source>Toxicol. In Vitro</source><year>2006</year><volume>20</volume><fpage>187</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2005.06.048</pub-id><pub-id pub-id-type="pmid">16289744</pub-id></element-citation></ref><ref id="B38-plants-09-01784"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brueggemeier</surname><given-names>R.W.</given-names></name></person-group><article-title>Aromatase, aromatase inhibitors, and breast cancer</article-title><source>Am. J. Ther.</source><year>2001</year><volume>8</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/00045391-200109000-00007</pub-id><pub-id pub-id-type="pmid">11550075</pub-id></element-citation></ref><ref id="B39-plants-09-01784"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouget</surname><given-names>C.</given-names></name><name><surname>Fagnere</surname><given-names>C.</given-names></name><name><surname>Basly</surname><given-names>J.P.</given-names></name><name><surname>Besson</surname><given-names>A.E.</given-names></name><name><surname>Champavier</surname><given-names>Y.</given-names></name><name><surname>Habrioux</surname><given-names>G.</given-names></name><name><surname>Chulia</surname><given-names>A.J.</given-names></name></person-group><article-title>Synthesis and aromatase inhibitory activity of flavanones</article-title><source>Pharm. Res.</source><year>2002</year><volume>19</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1023/A:1014490817731</pub-id><pub-id pub-id-type="pmid">11934235</pub-id></element-citation></ref><ref id="B40-plants-09-01784"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>L.J.</given-names></name><name><surname>Borradaile</surname><given-names>N.M.</given-names></name><name><surname>Huff</surname><given-names>M.W.</given-names></name></person-group><article-title>Antiatherogenic properties of naringenin, a citrus flavonoid</article-title><source>Cardiovasc. Ther.</source><year>1999</year><volume>17</volume><fpage>160</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3466.1999.tb00011.x</pub-id></element-citation></ref><ref id="B41-plants-09-01784"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutoh</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Fukuda</surname><given-names>K.</given-names></name><name><surname>Komatsu</surname><given-names>H.</given-names></name><name><surname>Enya</surname><given-names>T.</given-names></name><name><surname>Matsushima-Hibiya</surname><given-names>Y.</given-names></name><name><surname>Wakabayashi</surname><given-names>K.</given-names></name></person-group><article-title>Suppression by Flavonoids of Cyclooxygenase-2 Promoter-dependent Transcriptional Activity in Colon Cancer Cells: Structure-Activity Relationship</article-title><source>Cancer Sci.</source><year>2000</year><volume>91</volume><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2000.tb01000.x</pub-id><?supplied-pmid 10920275?><pub-id pub-id-type="pmid">10920275</pub-id></element-citation></ref><ref id="B42-plants-09-01784"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>M.U.</given-names></name><name><surname>Rahman</surname><given-names>M.U.</given-names></name><name><surname>Farooq</surname><given-names>A.</given-names></name><name><surname>Rashid</surname><given-names>S.M.</given-names></name><name><surname>Ahmad</surname><given-names>B.</given-names></name><name><surname>Muzamil</surname><given-names>S.</given-names></name></person-group><article-title>Naringenin (4,5,7-trihydroxyflavanone) suppresses the development of precancerous lesions via controlling hyperproliferation and inflammation in the colon of Wistar rats</article-title><source>Environ. Toxicol.</source><year>2018</year><volume>33</volume><fpage>422</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1002/tox.22528</pub-id><?supplied-pmid 29345053?><pub-id pub-id-type="pmid">29345053</pub-id></element-citation></ref><ref id="B43-plants-09-01784"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaii</surname><given-names>S.</given-names></name><name><surname>Tomono</surname><given-names>Y.</given-names></name><name><surname>Katase</surname><given-names>E.</given-names></name><name><surname>Ogawa</surname><given-names>K.</given-names></name><name><surname>Yano</surname><given-names>M.</given-names></name></person-group><article-title>Antiproliferative activity of flavonoids on several cancer cell lines</article-title><source>Biosci. Biotechnol. Biochem.</source><year>1999</year><volume>63</volume><fpage>896</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1271/bbb.63.896</pub-id><?supplied-pmid 10380632?><pub-id pub-id-type="pmid">10380632</pub-id></element-citation></ref><ref id="B44-plants-09-01784"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouget</surname><given-names>C.</given-names></name><name><surname>Lauthier</surname><given-names>F.</given-names></name><name><surname>Simon</surname><given-names>A.</given-names></name><name><surname>Fagnere</surname><given-names>C.</given-names></name><name><surname>Basly</surname><given-names>J.P.</given-names></name><name><surname>Delage</surname><given-names>C.</given-names></name><name><surname>Chulia</surname><given-names>A.J.</given-names></name></person-group><article-title>Flavonoids: Structural requirements for antiproliferative activity on breast cancer cells</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2001</year><volume>11</volume><fpage>3095</fpage><lpage>3097</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(01)00617-5</pub-id><pub-id pub-id-type="pmid">11720850</pub-id></element-citation></ref><ref id="B45-plants-09-01784"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W.S.</given-names></name><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Lu</surname><given-names>F.J.</given-names></name><name><surname>Chiang</surname><given-names>H.C.</given-names></name></person-group><article-title>Inhibitory effects of flavonoids on xanthine oxidase</article-title><source>Anticancer Res.</source><year>1993</year><volume>13</volume><fpage>2165</fpage><lpage>2170</lpage><?supplied-pmid 8297130?><pub-id pub-id-type="pmid">8297130</pub-id></element-citation></ref><ref id="B46-plants-09-01784"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwashita</surname><given-names>K.</given-names></name><name><surname>Kobori</surname><given-names>M.</given-names></name><name><surname>Yamaki</surname><given-names>K.</given-names></name><name><surname>Tsushida</surname><given-names>T.</given-names></name></person-group><article-title>Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2000</year><volume>64</volume><fpage>1813</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1271/bbb.64.1813</pub-id><?supplied-pmid 11055382?><pub-id pub-id-type="pmid">11055382</pub-id></element-citation></ref><ref id="B47-plants-09-01784"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Kawabata</surname><given-names>K.</given-names></name><name><surname>Kakumoto</surname><given-names>M.</given-names></name><name><surname>Makita</surname><given-names>H.</given-names></name><name><surname>Hara</surname><given-names>A.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name><name><surname>Kuki</surname><given-names>W.</given-names></name></person-group><article-title>Citrus auraptene inhibits chemically induced colonic aberrant crypt foci in male F344 rats</article-title><source>Carcinogenesis</source><year>1997</year><volume>18</volume><fpage>2155</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1093/carcin/18.11.2155</pub-id><pub-id pub-id-type="pmid">9395216</pub-id></element-citation></ref><ref id="B48-plants-09-01784"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrika</surname><given-names>B.B.</given-names></name><name><surname>Steephan</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>T.R.S.</given-names></name><name><surname>Sabu</surname><given-names>A.</given-names></name><name><surname>Haridas</surname><given-names>M.</given-names></name></person-group><article-title>Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors</article-title><source>Life Sci.</source><year>2016</year><volume>1</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2016.07.007</pub-id></element-citation></ref><ref id="B49-plants-09-01784"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>D.H.</given-names></name><name><surname>Jang</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Seol</surname><given-names>J.W.</given-names></name></person-group><article-title>Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma</article-title><source>Int. J. Med. Sci.</source><year>2020</year><volume>17</volume><fpage>3049</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.7150/ijms.44804</pub-id><pub-id pub-id-type="pmid">33173425</pub-id></element-citation></ref><ref id="B50-plants-09-01784"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.K.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Huang</surname><given-names>Y.T.</given-names></name><name><surname>Lin-Shiau</surname><given-names>S.Y.</given-names></name></person-group><article-title>Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin</article-title><source>J. Cell. Biochem.</source><year>1997</year><volume>28</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4644(1997)28/29+&#x0003c;39::AID-JCB5&#x0003e;3.0.CO;2-X</pub-id></element-citation></ref><ref id="B51-plants-09-01784"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>G.</given-names></name><name><surname>Shen</surname><given-names>F.</given-names></name><name><surname>Prajda</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Yeh</surname><given-names>A.</given-names></name><name><surname>Look</surname><given-names>K.Y.</given-names></name></person-group><article-title>Regulation of the signal transduction program by drugs</article-title><source>Adv. Enzym. Regul.</source><year>1995</year><volume>37</volume><fpage>35</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0065-2571(96)00025-8</pub-id></element-citation></ref><ref id="B52-plants-09-01784"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arul</surname><given-names>D.</given-names></name><name><surname>Subramanian</surname><given-names>P.</given-names></name></person-group><article-title>Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells</article-title><source>Pathol. Oncol. Res.</source><year>2013</year><volume>19</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1007/s12253-013-9641-1</pub-id><?supplied-pmid 23661153?><pub-id pub-id-type="pmid">23661153</pub-id></element-citation></ref><ref id="B53-plants-09-01784"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoimenov</surname><given-names>I.</given-names></name><name><surname>Helleday</surname><given-names>T.</given-names></name></person-group><article-title>PCNA on the crossroad of cancer</article-title><source>Biochem. Soc. Trans.</source><year>2009</year><volume>37</volume><issue-part>Pt 3</issue-part><fpage>605</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1042/BST0370605</pub-id><pub-id pub-id-type="pmid">19442257</pub-id></element-citation></ref><ref id="B54-plants-09-01784"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strzalka</surname><given-names>W.</given-names></name><name><surname>Ziemienowicz</surname><given-names>A.</given-names></name></person-group><article-title>Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation</article-title><source>Ann. Bot.</source><year>2010</year><volume>107</volume><fpage>1127</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1093/aob/mcq243</pub-id><?supplied-pmid 21169293?><pub-id pub-id-type="pmid">21169293</pub-id></element-citation></ref><ref id="B55-plants-09-01784"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Shen</surname><given-names>S.C.</given-names></name><name><surname>Lin</surname><given-names>H.U.</given-names></name></person-group><article-title>Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids</article-title><source>Biochem. Pharmacol.</source><year>2003</year><volume>66</volume><fpage>1139</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(03)00455-6</pub-id><pub-id pub-id-type="pmid">14505793</pub-id></element-citation></ref><ref id="B56-plants-09-01784"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>G.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways</article-title><source>Inflammopharmacology</source><year>2019</year><volume>27</volume><fpage>1021</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1007/s10787-018-00556-3</pub-id><?supplied-pmid 30941613?><pub-id pub-id-type="pmid">30941613</pub-id></element-citation></ref><ref id="B57-plants-09-01784"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>I.K.</given-names></name><name><surname>Lin-Shiau</surname><given-names>S.Y.</given-names></name><name><surname>Lin</surname><given-names>J.K.</given-names></name></person-group><article-title>Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells</article-title><source>Eur. J. Cancer</source><year>1999</year><volume>35</volume><fpage>1517</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00168-9</pub-id><pub-id pub-id-type="pmid">10673981</pub-id></element-citation></ref><ref id="B58-plants-09-01784"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzo</surname><given-names>P.</given-names></name><name><surname>Ascenzi</surname><given-names>P.</given-names></name><name><surname>Bulzomi</surname><given-names>P.</given-names></name><name><surname>Marino</surname><given-names>M.</given-names></name></person-group><article-title>The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor &#x003b1;-palmitoylation</article-title><source>Endocrinology</source><year>2008</year><volume>149</volume><fpage>2567</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1210/en.2007-1173</pub-id><pub-id pub-id-type="pmid">18239068</pub-id></element-citation></ref><ref id="B59-plants-09-01784"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totta</surname><given-names>P.</given-names></name><name><surname>Acconcia</surname><given-names>F.</given-names></name><name><surname>Leone</surname><given-names>S.</given-names></name><name><surname>Cardillo</surname><given-names>I.</given-names></name><name><surname>Marino</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms of Naringenin-induced Apoptotic Cascade in Cancer Cells: Involvement of Estrogen Receptor a and &#x000df; Signalling</article-title><source>IUBMB</source><year>2004</year><volume>56</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1080/15216540400010792</pub-id></element-citation></ref><ref id="B60-plants-09-01784"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulzomi</surname><given-names>P.</given-names></name><name><surname>Bolli</surname><given-names>Z.Z.</given-names></name><name><surname>Galluzzo</surname><given-names>P.</given-names></name><name><surname>Leone</surname><given-names>S.</given-names></name><name><surname>Acconcia</surname><given-names>F.</given-names></name><name><surname>Marino</surname><given-names>M.</given-names></name></person-group><article-title>Naringenin and 17&#x003b2;-estradiol coadministration prevents hormone-induced human cancer cell growth</article-title><source>IUBMB</source><year>2010</year><volume>62</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/iub.279</pub-id></element-citation></ref><ref id="B61-plants-09-01784"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>K.</given-names></name><name><surname>Nonaka</surname><given-names>M.</given-names></name><name><surname>Mochizuki</surname><given-names>H.</given-names></name><name><surname>Handa</surname><given-names>K.</given-names></name><name><surname>Hanada</surname><given-names>H.</given-names></name><name><surname>Hirota</surname><given-names>K.</given-names></name></person-group><article-title>Naringenin and hesperetin induce growth arrest, apoptosis, and cytoplasmic fat deposit in human preadipocytes</article-title><source>J. Agric. Food Chem.</source><year>2008</year><volume>56</volume><fpage>11030</fpage><lpage>11037</lpage><pub-id pub-id-type="doi">10.1021/jf801965n</pub-id><?supplied-pmid 18980325?><pub-id pub-id-type="pmid">18980325</pub-id></element-citation></ref><ref id="B62-plants-09-01784"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veiko</surname><given-names>A.G.</given-names></name><name><surname>Sekowski</surname><given-names>S.</given-names></name><name><surname>Lapshina</surname><given-names>E.A.</given-names></name><name><surname>Wilczewska</surname><given-names>A.Z.</given-names></name><name><surname>Markiewicz</surname><given-names>K.H.</given-names></name><name><surname>Zamaraeva</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>H.-C.</given-names></name><name><surname>Zavodnik</surname><given-names>I.B.</given-names></name></person-group><article-title>Flavonoids modulate liposomal membrane structure, regulate mitochondrial membrane permeability and prevent erythrocyte oxidative damage</article-title><source>Biochim. Biophys. Acta</source><year>2020</year><volume>1862</volume><fpage>183442</fpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2020.183442</pub-id><?supplied-pmid 32814117?><pub-id pub-id-type="pmid">32814117</pub-id></element-citation></ref><ref id="B63-plants-09-01784"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P.</given-names></name><name><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Angiogenesis in cancer and other diseases</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>249</fpage><pub-id pub-id-type="doi">10.1038/35025220</pub-id><?supplied-pmid 11001068?><pub-id pub-id-type="pmid">11001068</pub-id></element-citation></ref><ref id="B64-plants-09-01784"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N.</given-names></name><name><surname>Alitalo</surname><given-names>K.</given-names></name></person-group><article-title>Clinical applications of angiogenic growth factors and their inhibitors</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>1359</fpage><pub-id pub-id-type="doi">10.1038/70928</pub-id><?supplied-pmid 10581076?><pub-id pub-id-type="pmid">10581076</pub-id></element-citation></ref><ref id="B65-plants-09-01784"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosetti</surname><given-names>F.</given-names></name><name><surname>Ferrari</surname><given-names>N.</given-names></name><name><surname>De Flora</surname><given-names>S.</given-names></name><name><surname>Albini</surname><given-names>A.</given-names></name></person-group><article-title>Angioprevention&#x02019;: Angiogenesis is a common and key target for cancer chemopreventive agents</article-title><source>FASEB J.</source><year>2002</year><volume>16</volume><fpage>2</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1096/fj.01-0300rev</pub-id><?supplied-pmid 11772931?><pub-id pub-id-type="pmid">11772931</pub-id></element-citation></ref><ref id="B66-plants-09-01784"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Ambasta</surname><given-names>P.K.</given-names></name><name><surname>Kumar</surname><given-names>P.</given-names></name></person-group><article-title>Combinatorial antitumor effect of naringenin and curcumin elicit angioinhibitory activities in vivo</article-title><source>Nutr. Cancer</source><year>2012</year><volume>64</volume><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1080/01635581.2012.686648</pub-id><pub-id pub-id-type="pmid">22642894</pub-id></element-citation></ref><ref id="B67-plants-09-01784"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name></person-group><article-title>Naringenin decreases invasiveness and metastasis by inhibiting TGF-&#x003b2;-induced epithelial to mesenchymal transition in pancreatic cancer cells</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>50956</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0050956</pub-id></element-citation></ref><ref id="B68-plants-09-01784"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhakar</surname><given-names>P.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Doble</surname><given-names>M.</given-names></name></person-group><article-title>Combination therapy: A new strategy to manage diabetes and its complications</article-title><source>Phytomedicine</source><year>2014</year><volume>21</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2013.08.020</pub-id><pub-id pub-id-type="pmid">24074610</pub-id></element-citation></ref><ref id="B69-plants-09-01784"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>J.S.</given-names></name><name><surname>Gearry</surname><given-names>R.B.</given-names></name><name><surname>Muir</surname><given-names>J.G.</given-names></name><name><surname>Irving</surname><given-names>P.M.</given-names></name><name><surname>Rose</surname><given-names>R.</given-names></name><name><surname>Rosella</surname><given-names>O.</given-names></name><name><surname>Gibson</surname><given-names>P.R.</given-names></name></person-group><article-title>Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon</article-title><source>Aliment. Pharmacol. Ther.</source><year>2010</year><volume>31</volume><fpage>874</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2010.04237.x</pub-id><pub-id pub-id-type="pmid">20102355</pub-id></element-citation></ref><ref id="B70-plants-09-01784"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priscilla</surname><given-names>D.H.</given-names></name><name><surname>Roy</surname><given-names>D.</given-names></name><name><surname>Suresh</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Thirumurugan</surname><given-names>K.</given-names></name></person-group><article-title>Naringenin inhibits &#x003b1;-glucosidase activity: A promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats</article-title><source>Chem. -Biol. Interact.</source><year>2014</year><volume>210</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2013.12.014</pub-id><pub-id pub-id-type="pmid">24412302</pub-id></element-citation></ref><ref id="B71-plants-09-01784"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez-Salgado</surname><given-names>J.</given-names></name><name><surname>Ortiz-Andrade</surname><given-names>R.</given-names></name><name><surname>Aguirre-Crespo</surname><given-names>F.</given-names></name><name><surname>Vergara-Galicia</surname><given-names>J.</given-names></name><name><surname>Le&#x000f3;n-Rivera</surname><given-names>I.</given-names></name><name><surname>Montes</surname><given-names>S.</given-names></name><name><surname>Estrada-Soto</surname><given-names>S.</given-names></name></person-group><article-title>Hypoglycemic, vasorelaxant and hepatoprotective effects of Cochlospermum vitifolium (Willd.) Sprengel: A potential agent for the treatment of metabolic syndrome</article-title><source>J. Ethnopharmacol.</source><year>2007</year><volume>109</volume><fpage>400</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2006.08.008</pub-id><?supplied-pmid 16978815?><pub-id pub-id-type="pmid">16978815</pub-id></element-citation></ref><ref id="B72-plants-09-01784"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannappan</surname><given-names>S.</given-names></name><name><surname>Anuradha</surname><given-names>C.V.</given-names></name></person-group><article-title>Naringenin enhances insulin-stimulated tyrosine phosphorylation and improves the cellular actions of insulin in a dietary model of metabolic syndrome</article-title><source>Eur. J. Nutr.</source><year>2010</year><volume>49</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s00394-009-0054-6</pub-id><pub-id pub-id-type="pmid">19727895</pub-id></element-citation></ref><ref id="B73-plants-09-01784"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulvihill</surname><given-names>E.</given-names></name><name><surname>Allister</surname><given-names>E.M.</given-names></name><name><surname>Sutherland</surname><given-names>B.G.</given-names></name><name><surname>Telford</surname><given-names>D.E.</given-names></name><name><surname>Sawyez</surname><given-names>C.G.</given-names></name><name><surname>Edwards</surname><given-names>J.Y.</given-names></name><name><surname>Huff</surname><given-names>M.H.</given-names></name></person-group><article-title>Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor&#x02013;null mice with diet-induced insulin resistance</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>2198</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.2337/db09-0634</pub-id><?supplied-pmid 19592617?><pub-id pub-id-type="pmid">19592617</pub-id></element-citation></ref><ref id="B74-plants-09-01784"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purushotham</surname><given-names>A.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Belury</surname><given-names>M.</given-names></name></person-group><article-title>The citrus fruit flavonoid naringenin suppresses hepatic glucose production from Fao hepatoma cells</article-title><source>Mol. Nutr. Food Res.</source><year>2009</year><volume>53</volume><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200700514</pub-id><?supplied-pmid 19035551?><pub-id pub-id-type="pmid">19035551</pub-id></element-citation></ref><ref id="B75-plants-09-01784"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creely</surname><given-names>S.J.</given-names></name><name><surname>McTernan</surname><given-names>P.G.</given-names></name><name><surname>Kusminski</surname><given-names>C.M.</given-names></name><name><surname>Fisher</surname><given-names>F.M.</given-names></name><name><surname>Silva</surname><given-names>N.</given-names></name><name><surname>Khanolkar</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><article-title>Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes</article-title><source>Am. J. Physiol.</source><year>2007</year><volume>292</volume><fpage>740</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00302.2006</pub-id><?supplied-pmid 17090751?><pub-id pub-id-type="pmid">17090751</pub-id></element-citation></ref><ref id="B76-plants-09-01784"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>H.C.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Choi</surname><given-names>S.J.</given-names></name><name><surname>Cho</surname><given-names>H.Y.</given-names></name><name><surname>Hong</surname><given-names>B.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name></person-group><article-title>Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia</article-title><source>Dement. Geriatr. Cogn. Disord.</source><year>2004</year><volume>17</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1159/000076349</pub-id><pub-id pub-id-type="pmid">14739537</pub-id></element-citation></ref><ref id="B77-plants-09-01784"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Kokoeva</surname><given-names>M.V.</given-names></name><name><surname>Inouye</surname><given-names>K.</given-names></name><name><surname>Tzameli</surname><given-names>I.</given-names></name><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>Flier</surname><given-names>J.S.</given-names></name></person-group><article-title>TLR4 links innate immunity and fatty acid&#x02013;induced insulin resistance</article-title><source>J. Clin. Investig.</source><year>2006</year><volume>11</volume><fpage>3015</fpage><lpage>3025</lpage><pub-id pub-id-type="doi">10.1172/JCI28898</pub-id></element-citation></ref><ref id="B78-plants-09-01784"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Watanabe</surname><given-names>W.</given-names></name><name><surname>Oomagari</surname><given-names>H.</given-names></name><name><surname>Tsuruta</surname><given-names>E.</given-names></name><name><surname>Shida</surname><given-names>M.</given-names></name><name><surname>Kurokawa</surname><given-names>M.</given-names></name></person-group><article-title>Citrus flavonoid naringenin inhibits TLR2 expression in adipocytes</article-title><source>J. Nutr. Biochem.</source><year>2013</year><volume>24</volume><fpage>1276</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2012.10.003</pub-id><pub-id pub-id-type="pmid">23333096</pub-id></element-citation></ref><ref id="B79-plants-09-01784"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Ishida</surname><given-names>A.</given-names></name><name><surname>Watanabe</surname><given-names>W.</given-names></name><name><surname>Narumi</surname><given-names>K.</given-names></name><name><surname>Atsumi</surname><given-names>T.</given-names></name><name><surname>Kurokawa</surname><given-names>M.</given-names></name></person-group><article-title>Naringenin suppresses macrophage infiltration into adipose tissue in an early phase of high-fat diet-induced obesity</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2014</year><volume>454</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.10.038</pub-id><pub-id pub-id-type="pmid">25450363</pub-id></element-citation></ref><ref id="B80-plants-09-01784"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>S.</given-names></name><name><surname>Joghataei</surname><given-names>M.T.</given-names></name><name><surname>Mohseni</surname><given-names>S.</given-names></name><name><surname>Baluchnejadmojarad</surname><given-names>T.</given-names></name><name><surname>Bagheri</surname><given-names>M.</given-names></name><name><surname>Khamse</surname><given-names>S.</given-names></name><name><surname>Roghani</surname><given-names>M.</given-names></name></person-group><article-title>Naringenin improves learning and memory in an Alzheimer&#x02019;s disease rat model: Insights into the underlying mechanisms</article-title><source>Eur. J. Pharmacol.</source><year>2015</year><volume>764</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.07.001</pub-id><pub-id pub-id-type="pmid">26148826</pub-id></element-citation></ref><ref id="B81-plants-09-01784"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>R.M.</given-names></name></person-group><article-title>Lipids and lipoproteins in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1496</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.6.1496</pub-id><?supplied-pmid 15161808?><pub-id pub-id-type="pmid">15161808</pub-id></element-citation></ref><ref id="B82-plants-09-01784"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borradaile</surname><given-names>N.M.</given-names></name><name><surname>de Dreu</surname><given-names>L.E.</given-names></name><name><surname>Huff</surname><given-names>M.W.</given-names></name></person-group><article-title>Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>2554</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.10.2554</pub-id><?supplied-pmid 14514640?><pub-id pub-id-type="pmid">14514640</pub-id></element-citation></ref><ref id="B83-plants-09-01784"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>D.</given-names></name><name><surname>Fonseca</surname><given-names>V.</given-names></name></person-group><article-title>From guideline to patient: A review of recent recommendations for pharmacotherapy of painful diabetic neuropathy</article-title><source>J. Diabetes Complicat.</source><year>2015</year><volume>29</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2014.08.008</pub-id><?supplied-pmid 25239450?><pub-id pub-id-type="pmid">25239450</pub-id></element-citation></ref><ref id="B84-plants-09-01784"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesfaye</surname><given-names>S.</given-names></name></person-group><article-title>Advances in the management of diabetic peripheral neuropathy</article-title><source>Curr. Opin. Supportive Palliat. Care</source><year>2009</year><volume>3</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1097/SPC.0b013e32832b7df5</pub-id></element-citation></ref><ref id="B85-plants-09-01784"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesfaye</surname><given-names>S.</given-names></name><name><surname>Selvarajah</surname><given-names>D.</given-names></name></person-group><article-title>Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy</article-title><source>Diabetes/Metab. Res. Rev.</source><year>2012</year><volume>28</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1002/dmrr.2239</pub-id><?supplied-pmid 22271716?><pub-id pub-id-type="pmid">22271716</pub-id></element-citation></ref><ref id="B86-plants-09-01784"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasanein</surname><given-names>P.</given-names></name><name><surname>Fuseli</surname><given-names>F.</given-names></name></person-group><article-title>Role of naringenin in protection against diabetic hyperalgesia and tactile allodynia in male Wistar rats</article-title><source>J. Physiol. Biochem.</source><year>2014</year><volume>70</volume><fpage>997</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1007/s13105-014-0369-5</pub-id><?supplied-pmid 25407136?><pub-id pub-id-type="pmid">25407136</pub-id></element-citation></ref><ref id="B87-plants-09-01784"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>V.</given-names></name><name><surname>Jaggi</surname><given-names>A.S.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name></person-group><article-title>Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats</article-title><source>Pharmacol. Res.</source><year>2009</year><volume>59</volume><fpage>385</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2009.02.001</pub-id><pub-id pub-id-type="pmid">19429470</pub-id></element-citation></ref><ref id="B88-plants-09-01784"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freshwater</surname><given-names>J.D.</given-names></name><name><surname>Svensson</surname><given-names>C.I.</given-names></name><name><surname>Malmberg</surname><given-names>A.B.</given-names></name><name><surname>Calcutt</surname><given-names>N.A.</given-names></name></person-group><article-title>Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>2249</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.7.2249</pub-id><pub-id pub-id-type="pmid">12086957</pub-id></element-citation></ref><ref id="B89-plants-09-01784"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>K.</given-names></name><name><surname>Khan</surname><given-names>I.I.</given-names></name><name><surname>Akash</surname><given-names>M.</given-names></name><name><surname>Jabeen</surname><given-names>K.</given-names></name><name><surname>Haider</surname><given-names>K.</given-names></name></person-group><article-title>Naringenin downregulates inflammation-mediated nitric oxide overproduction and potentiates endogenous antioxidant status during hyperglycemia</article-title><source>J. Food Biochem.</source><year>2020</year><fpage>e13422</fpage><comment>advance online publication</comment><pub-id pub-id-type="doi">10.1111/jfbc.13422</pub-id><pub-id pub-id-type="pmid">32770581</pub-id></element-citation></ref><ref id="B90-plants-09-01784"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>C.L.</given-names></name><name><surname>Weng</surname><given-names>C.S.</given-names></name><name><surname>Chang</surname><given-names>N.C.</given-names></name><name><surname>Lin</surname><given-names>J.S.</given-names></name><name><surname>Kao</surname><given-names>S.T.</given-names></name><name><surname>Ho</surname><given-names>F.M.</given-names></name></person-group><article-title>Naringenin more effectively inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in macrophages than in microglia</article-title><source>Nutr. Res.</source><year>2010</year><volume>30</volume><fpage>858</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2010.10.011</pub-id><pub-id pub-id-type="pmid">21147369</pub-id></element-citation></ref><ref id="B91-plants-09-01784"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>R.Q.</given-names></name><name><surname>Sterling</surname><given-names>R.K.</given-names></name></person-group><article-title>Acute liver failure</article-title><source>J. Clin. Gastroenterol.</source><year>2001</year><volume>33</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1097/00004836-200109000-00005</pub-id><?supplied-pmid 11500606?><pub-id pub-id-type="pmid">11500606</pub-id></element-citation></ref><ref id="B92-plants-09-01784"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name><name><surname>Andrade</surname><given-names>R.J.</given-names></name><name><surname>Merz</surname><given-names>M.</given-names></name></person-group><article-title>Drug-induced liver injury: Recent advances in diagnosis and risk assessment</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>1154</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-313369</pub-id><?supplied-pmid 28341748?><pub-id pub-id-type="pmid">28341748</pub-id></element-citation></ref><ref id="B93-plants-09-01784"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Golli-Bennour</surname><given-names>E.</given-names></name><name><surname>Timoumi</surname><given-names>R.</given-names></name><name><surname>Annaibi</surname><given-names>E.</given-names></name><name><surname>Mokni</surname><given-names>M.</given-names></name><name><surname>Omezzine</surname><given-names>A.</given-names></name><name><surname>Bacha</surname><given-names>H.</given-names></name><name><surname>Abid-Essefi</surname><given-names>S.</given-names></name></person-group><article-title>Protective effects of kefir against deltamethrin-induced hepatotoxicity in rats</article-title><source>Envrion. Sci. Pollut. Res. Int.</source><year>2019</year><volume>26</volume><fpage>18856</fpage><lpage>18865</lpage><pub-id pub-id-type="doi">10.1007/s11356-019-05253-4</pub-id><?supplied-pmid 31062243?><pub-id pub-id-type="pmid">31062243</pub-id></element-citation></ref><ref id="B94-plants-09-01784"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.Y.</given-names></name><name><surname>Chang</surname><given-names>H.H.</given-names></name><name><surname>Wu</surname><given-names>M.Y.</given-names></name><name><surname>Lin</surname><given-names>H.C.</given-names></name></person-group><article-title>Yin-Chen-Hao-Tang ameliorates obstruction-induced hepatic apoptosis in rats</article-title><source>J. Pharm. Pharmacol.</source><year>2007</year><volume>59</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1211/jpp.59.4.0014</pub-id><pub-id pub-id-type="pmid">17430643</pub-id></element-citation></ref><ref id="B95-plants-09-01784"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>H.Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>Z.J.</given-names></name><name><surname>Lao</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>C.W.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name></person-group><article-title>Role of Oxidative Stress and Antioxidants in Liver Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>26087</fpage><lpage>26124</lpage><pub-id pub-id-type="doi">10.3390/ijms161125942</pub-id><pub-id pub-id-type="pmid">26540040</pub-id></element-citation></ref><ref id="B96-plants-09-01784"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermenean</surname><given-names>A.</given-names></name><name><surname>Ardelean</surname><given-names>A.</given-names></name><name><surname>Stan</surname><given-names>M.</given-names></name><name><surname>Herman</surname><given-names>H.</given-names></name><name><surname>Mihali</surname><given-names>C.V.</given-names></name><name><surname>Costache</surname><given-names>M.</given-names></name><name><surname>Dinischiotu</surname><given-names>A.</given-names></name></person-group><article-title>Protective effects of naringenin on carbon tetrachloride-induced acute nephrotoxicity in mouse kidney</article-title><source>Chem. Biol. Interact.</source><year>2013</year><volume>205</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2013.06.016</pub-id><pub-id pub-id-type="pmid">23845967</pub-id></element-citation></ref><ref id="B97-plants-09-01784"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mershiba</surname><given-names>S.D.</given-names></name><name><surname>Dassprakash</surname><given-names>M.V.</given-names></name><name><surname>Saraswathy</surname><given-names>S.D.</given-names></name></person-group><article-title>Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats</article-title><source>Mol. Biol. Rep.</source><year>2013</year><volume>40</volume><fpage>3681</fpage><lpage>3691</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-2444-8</pub-id><pub-id pub-id-type="pmid">23283742</pub-id></element-citation></ref><ref id="B98-plants-09-01784"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renugadevi</surname><given-names>J.</given-names></name><name><surname>Prabu</surname><given-names>S.M.</given-names></name></person-group><article-title>Naringenin protects against cadmium-induced oxidative renal dysfunction in rats</article-title><source>Toxicology</source><year>2009</year><volume>256</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2008.11.012</pub-id><pub-id pub-id-type="pmid">19063931</pub-id></element-citation></ref><ref id="B99-plants-09-01784"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez-Aquino</surname><given-names>E.</given-names></name><name><surname>Muriel</surname><given-names>P.</given-names></name></person-group><article-title>Beneficial effects of naringenin in liver diseases: Molecular mechanisms</article-title><source>World J. Gastroenterol.</source><year>2018</year><volume>24</volume><fpage>1679</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.3748/wjg.v24.i16.1679</pub-id><pub-id pub-id-type="pmid">29713125</pub-id></element-citation></ref><ref id="B100-plants-09-01784"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashmi</surname><given-names>R.</given-names></name><name><surname>Magesh</surname><given-names>S.B.</given-names></name><name><surname>Mohanram</surname><given-names>R.K.</given-names></name><name><surname>Suryanarayanan</surname><given-names>S.</given-names></name><name><surname>Venkata SubbaRao</surname><given-names>M.</given-names></name></person-group><article-title>Antioxidant Potential of Naringenin Helps to Protect Liver Tissue from Streptozotocin-Induced Damage</article-title><source>Rep. Biochem. Mol. Biol.</source><year>2018</year><volume>7</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">30324121</pub-id></element-citation></ref><ref id="B101-plants-09-01784"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauchen</surname><given-names>J.</given-names></name><name><surname>Huml</surname><given-names>L.</given-names></name><name><surname>Rimpelova</surname><given-names>S.</given-names></name><name><surname>Jur&#x000e1;&#x00161;ek</surname><given-names>M.</given-names></name></person-group><article-title>Flavonoids and Related Members of the Aromatic Polyketide Group in Human Health and Disease: Do They Really Work?</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3846</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25173846</pub-id><?supplied-pmid 32847100?><pub-id pub-id-type="pmid">32847100</pub-id></element-citation></ref><ref id="B102-plants-09-01784"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chetia</surname><given-names>P.P.</given-names></name><name><surname>Bala</surname><given-names>A.</given-names></name><name><surname>Khandelwal</surname><given-names>B.</given-names></name><name><surname>Haldar</surname><given-names>P.</given-names></name></person-group><article-title>Comparative in vitro free radical scavenging property of &#x000e2;-carotene and naringenin with respect to vitamin C and N-acetyl cysteine</article-title><source>Pharmacologia</source><year>2012</year><volume>3</volume><fpage>724</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.5567/pharmacologia.2012.724.728</pub-id></element-citation></ref><ref id="B103-plants-09-01784"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez-Aquino</surname><given-names>E.</given-names></name><name><surname>Zarco</surname><given-names>N.</given-names></name><name><surname>Casas-Grajales</surname><given-names>S.</given-names></name><name><surname>Ramos-Tovar</surname><given-names>E.</given-names></name><name><surname>Flores-Beltr&#x000e1;n</surname><given-names>R.E.</given-names></name><name><surname>Arauz</surname><given-names>J.</given-names></name><name><surname>Shibayama</surname><given-names>M.</given-names></name><name><surname>Favari</surname><given-names>L.</given-names></name><name><surname>Tsutsumi</surname><given-names>V.</given-names></name><name><surname>Segovia</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Naringenin prevents experimental liver fibrosis by blocking TGF&#x003b2;-Smad3 and JNK-Smad3 pathways</article-title><source>World J. Gastroenterol.</source><year>2017</year><volume>23</volume><fpage>4354</fpage><lpage>4368</lpage><pub-id pub-id-type="doi">10.3748/wjg.v23.i24.4354</pub-id><pub-id pub-id-type="pmid">28706418</pub-id></element-citation></ref><ref id="B104-plants-09-01784"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskaug</surname><given-names>J.O.</given-names></name><name><surname>Carlsen</surname><given-names>H.</given-names></name><name><surname>Myhrstad</surname><given-names>M.C.</given-names></name><name><surname>Blomhoff</surname><given-names>R.</given-names></name></person-group><article-title>Polyphenols and glutathione synthesis regulation</article-title><source>Am. J. Clin. Nutr.</source><year>2005</year><volume>81</volume><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1093/ajcn/81.1.277S</pub-id><?supplied-pmid 15640491?><pub-id pub-id-type="pmid">15640491</pub-id></element-citation></ref><ref id="B105-plants-09-01784"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>H.</given-names></name><name><surname>Takamatsu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Huh</surname><given-names>N.H.</given-names></name><name><surname>Sakaguchi</surname><given-names>M.</given-names></name></person-group><article-title>NRF2 Regulates PINK1 Expression under Oxidative Stress Conditions</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0142438</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0142438</pub-id><pub-id pub-id-type="pmid">26555609</pub-id></element-citation></ref><ref id="B106-plants-09-01784"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name></person-group><article-title>Naringenin as a potential immunomodulator in therapeutics</article-title><source>Pharm. Res.</source><year>2018</year><volume>135</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.08.002</pub-id></element-citation></ref><ref id="B107-plants-09-01784"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermenean</surname><given-names>A.</given-names></name><name><surname>Ardelean</surname><given-names>A.</given-names></name><name><surname>Stan</surname><given-names>M.</given-names></name><name><surname>Hadaruga</surname><given-names>N.</given-names></name><name><surname>Mihali</surname><given-names>C.V.</given-names></name><name><surname>Costache</surname><given-names>M.</given-names></name><name><surname>Dinischiotu</surname><given-names>A.</given-names></name></person-group><article-title>Antioxidant and hepatoprotective effects of naringenin and its &#x003b2;-cyclodextrin formulation in mice intoxicated with carbon tetrachloride: A comparative study</article-title><source>J. Med. Food</source><year>2014</year><volume>17</volume><fpage>670</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1089/jmf.2013.0007</pub-id><pub-id pub-id-type="pmid">24611872</pub-id></element-citation></ref><ref id="B108-plants-09-01784"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>F.L.</given-names></name><name><surname>Wu</surname><given-names>T.H.</given-names></name><name><surname>Lin</surname><given-names>L.T.</given-names></name><name><surname>Cham</surname><given-names>T.M.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name></person-group><article-title>Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl4-induced acute liver failure</article-title><source>Pharm. Res.</source><year>2007</year><volume>26</volume><fpage>893</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9791-0</pub-id></element-citation></ref><ref id="B109-plants-09-01784"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Flavonoids from Aurantii Fructus Immaturus and Aurantii Fructus: Promising phytomedicines for the treatment of liver diseases</article-title><source>Chin. Med.</source><year>2020</year><volume>15</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/s13020-020-00371-5</pub-id><pub-id pub-id-type="pmid">32863858</pub-id></element-citation></ref><ref id="B110-plants-09-01784"><label>110.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Kuncio</surname><given-names>G.S.</given-names></name><name><surname>Zern</surname><given-names>M.A.</given-names></name></person-group><source>Liver Growth Repair: From Basic Science to Clinical Practice</source><publisher-name>Chapman and Hall</publisher-name><publisher-loc>London, UK</publisher-loc><year>1998</year></element-citation></ref><ref id="B111-plants-09-01784"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajappa</surname><given-names>R.</given-names></name><name><surname>Sireesh</surname><given-names>D.</given-names></name><name><surname>Salai</surname><given-names>M.B.</given-names></name><name><surname>Ramkumar</surname><given-names>K.M.</given-names></name><name><surname>Sarvajayakesavulu</surname><given-names>S.</given-names></name><name><surname>Madhunapantula</surname><given-names>S.V.</given-names></name></person-group><article-title>Treatment with naringenin elevates the activity of transcription factor nrf2 to protect pancreatic &#x003b2;-cells from streptozotocin-induced diabetes in vitro and in vivo</article-title><source>Front. Pharm.</source><year>2019</year><volume>9</volume><fpage>1562</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01562</pub-id></element-citation></ref><ref id="B112-plants-09-01784"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kegel</surname><given-names>V.</given-names></name><name><surname>Pfeiffer</surname><given-names>E.</given-names></name><name><surname>Burkhardt</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>J.L.</given-names></name><name><surname>Zeilinger</surname><given-names>K.</given-names></name><name><surname>N&#x000fc;ssler</surname><given-names>A.K.</given-names></name><name><surname>Seehofer</surname><given-names>D.</given-names></name><name><surname>Damm</surname><given-names>G.</given-names></name></person-group><article-title>Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human in Vitro Liver Model: An Approach to Study DILI</article-title><source>Mediat. Inflamm.</source><year>2015</year><volume>2015</volume><fpage>640631</fpage><pub-id pub-id-type="doi">10.1155/2015/640631</pub-id><?supplied-pmid 26491234?><pub-id pub-id-type="pmid">26491234</pub-id></element-citation></ref><ref id="B113-plants-09-01784"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>R.G.</given-names></name></person-group><article-title>Cellular sources of extracellular matrix in hepatic fibrosis</article-title><source>Clin. Liver Dis.</source><year>2008</year><volume>2</volume><fpage>759</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2008.07.008</pub-id><?supplied-pmid 18984465?><pub-id pub-id-type="pmid">18984465</pub-id></element-citation></ref><ref id="B114-plants-09-01784"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arriazu</surname><given-names>E.</given-names></name><name><surname>Ruiz de Galarreta</surname><given-names>M.</given-names></name><name><surname>Cubero</surname><given-names>F.J.</given-names></name><name><surname>Varela-Rey</surname><given-names>M.</given-names></name><name><surname>P&#x000e9;rez de Obanos</surname><given-names>M.P.</given-names></name><name><surname>Leung</surname><given-names>T.M.</given-names></name><name><surname>Lopategi</surname><given-names>A.</given-names></name><name><surname>Benedicto</surname><given-names>A.</given-names></name><name><surname>Abraham-Enachescu</surname><given-names>I.</given-names></name><name><surname>Nieto</surname><given-names>N.</given-names></name></person-group><article-title>Extracellular matrix and liver disease</article-title><source>Antioxid. Redox Signal.</source><year>2014</year><volume>21</volume><fpage>1078</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1089/ars.2013.5697</pub-id><?supplied-pmid 24219114?><pub-id pub-id-type="pmid">24219114</pub-id></element-citation></ref><ref id="B115-plants-09-01784"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>A.M.</given-names></name><name><surname>Hernandez Bautista</surname><given-names>R.J.</given-names></name><name><surname>Sandhu</surname><given-names>M.A.</given-names></name><name><surname>Hussein</surname><given-names>O.E.</given-names></name></person-group><article-title>Beneficial effects of citrus flavonoids on cardiovascular and metabolic health</article-title><source>Oxidative Med. Cell. Longev.</source><year>2019</year><pub-id pub-id-type="doi">10.1155/2019/5484138</pub-id></element-citation></ref><ref id="B116-plants-09-01784"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chtourou</surname><given-names>Y.</given-names></name><name><surname>Fetoui</surname><given-names>H.</given-names></name><name><surname>Jemai</surname><given-names>R.</given-names></name><name><surname>Slima</surname><given-names>A.B.</given-names></name><name><surname>Makni</surname><given-names>M.</given-names></name><name><surname>Gdoura</surname><given-names>R.</given-names></name></person-group><article-title>Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor &#x003ba;B pathway</article-title><source>Eur. J. Pharmacol.</source><year>2015</year><volume>746</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.10.027</pub-id><pub-id pub-id-type="pmid">25446569</pub-id></element-citation></ref><ref id="B117-plants-09-01784"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annadurai</surname><given-names>T.</given-names></name><name><surname>Thomas</surname><given-names>P.</given-names></name><name><surname>Geraldine</surname><given-names>P.</given-names></name></person-group><article-title>Ameliorative effect of naringenin on hyperglycemia-mediated inflammation in hepatic and pancreatic tissues of Wistar rats with streptozotocin-nicotinamide-induced experimental diabetes mellitus</article-title><source>Free Radic. Res.</source><year>2013</year><volume>47</volume><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.3109/10715762.2013.823643</pub-id><pub-id pub-id-type="pmid">23841752</pub-id></element-citation></ref><ref id="B118-plants-09-01784"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Kong</surname><given-names>J.</given-names></name></person-group><article-title>Oxidative stress in neurodegenerative diseases</article-title><source>Neural Regen. Res.</source><year>2012</year><volume>7</volume><fpage>376</fpage><pub-id pub-id-type="doi">10.3969/j.issn.1673-5374.2012.05.009</pub-id><pub-id pub-id-type="pmid">25774178</pub-id></element-citation></ref><ref id="B119-plants-09-01784"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drey</surname><given-names>M.</given-names></name><name><surname>Hasmann</surname><given-names>S.E.</given-names></name><name><surname>Krenovsky</surname><given-names>J.P.</given-names></name><name><surname>Hobert</surname><given-names>M.A.</given-names></name><name><surname>Straub</surname><given-names>S.</given-names></name><name><surname>Elshehabi</surname><given-names>M.</given-names></name><name><surname>Suenkel</surname><given-names>U.</given-names></name></person-group><article-title>Associations between Early Markers of Parkinson&#x02019;s Disease and Sarcopenia</article-title><source>Front. Aging Neurosci.</source><year>2017</year><volume>9</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2017.00053</pub-id><pub-id pub-id-type="pmid">28326036</pub-id></element-citation></ref><ref id="B120-plants-09-01784"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ungerstedt</surname><given-names>U.</given-names></name></person-group><article-title>6-Hydroxy-dopamine induced degeneration of central monoamine neurons</article-title><source>Eur. J. Pharmacol.</source><year>1968</year><volume>5</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(68)90164-7</pub-id><pub-id pub-id-type="pmid">5718510</pub-id></element-citation></ref><ref id="B121-plants-09-01784"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zbarsky</surname><given-names>V.</given-names></name><name><surname>Datla</surname><given-names>K.P.</given-names></name><name><surname>Parkar</surname><given-names>S.</given-names></name><name><surname>Rai</surname><given-names>D.K.</given-names></name><name><surname>Aruoma</surname><given-names>O.I.</given-names></name><name><surname>Dexter</surname><given-names>D.T.</given-names></name></person-group><article-title>Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson&#x02019;s disease</article-title><source>Free Radic. Res.</source><year>2005</year><volume>39</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1080/10715760500233113</pub-id><pub-id pub-id-type="pmid">16298737</pub-id></element-citation></ref><ref id="B122-plants-09-01784"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a p-glycoprotein modulator</article-title><source>J. Agric. Food Chem.</source><year>2002</year><volume>50</volume><fpage>6669</fpage><lpage>6674</lpage><pub-id pub-id-type="doi">10.1021/jf020603p</pub-id><?supplied-pmid 12405759?><pub-id pub-id-type="pmid">12405759</pub-id></element-citation></ref><ref id="B123-plants-09-01784"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>K.A.</given-names></name><name><surname>Dobbie</surname><given-names>M.S.</given-names></name><name><surname>Kuhnle</surname><given-names>G.</given-names></name><name><surname>Proteggente</surname><given-names>A.R.</given-names></name><name><surname>Abbott</surname><given-names>N.J.</given-names></name><name><surname>Rice-Evans</surname><given-names>C.</given-names></name></person-group><article-title>Interaction between flavonoids and the blood&#x02013;brain barrier: In vitro studies</article-title><source>J. Neurochem.</source><year>2003</year><volume>85</volume><fpage>180</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01652.x</pub-id><?supplied-pmid 12641740?><pub-id pub-id-type="pmid">12641740</pub-id></element-citation></ref><ref id="B124-plants-09-01784"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouri</surname><given-names>Z.</given-names></name><name><surname>Fakhri</surname><given-names>S.</given-names></name><name><surname>El-Senduny</surname><given-names>F.F.</given-names></name><name><surname>Sanadgol</surname><given-names>N.</given-names></name><name><surname>Abd-ElGhani</surname><given-names>G.E.</given-names></name><name><surname>Farzaei</surname><given-names>M.H.</given-names></name><name><surname>Chen</surname><given-names>J.T.</given-names></name></person-group><article-title>On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>690</elocation-id><pub-id pub-id-type="doi">10.3390/biom9110690</pub-id><?supplied-pmid 31684142?><pub-id pub-id-type="pmid">31684142</pub-id></element-citation></ref><ref id="B125-plants-09-01784"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeline</surname><given-names>M.S.</given-names></name><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Ambasta</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>P.</given-names></name></person-group><article-title>Sesamol and naringenin reverse the effect of rotenone-induced PD rat model</article-title><source>Neuroscience</source><year>2013</year><volume>254</volume><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.09.029</pub-id><pub-id pub-id-type="pmid">24070629</pub-id></element-citation></ref><ref id="B126-plants-09-01784"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats</article-title><source>Neurol. Sci.</source><year>2014</year><volume>35</volume><fpage>741</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s10072-013-1594-3</pub-id><pub-id pub-id-type="pmid">24337945</pub-id></element-citation></ref><ref id="B127-plants-09-01784"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarubbo</surname><given-names>F.</given-names></name><name><surname>Ramis</surname><given-names>M.</given-names></name><name><surname>Kienzer</surname><given-names>C.</given-names></name><name><surname>Aparicio</surname><given-names>S.</given-names></name><name><surname>Esteban</surname><given-names>S.</given-names></name><name><surname>Miralles</surname><given-names>A.</given-names></name><name><surname>Moranta</surname><given-names>D.</given-names></name></person-group><article-title>Chronic silymarin, quercetin and naringenin treatments increase monoamines synthesis and hippocampal SIRT1 levels improving cognition in aged rats</article-title><source>J. Neuroimmune Pharmacol.</source><year>2018</year><volume>13</volume><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s11481-017-9759-0</pub-id><pub-id pub-id-type="pmid">28808887</pub-id></element-citation></ref><ref id="B128-plants-09-01784"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Ashafaq</surname><given-names>M.</given-names></name><name><surname>Islam</surname><given-names>F.</given-names></name><name><surname>Wagner</surname><given-names>A.</given-names></name><name><surname>Safhi</surname><given-names>M.</given-names></name></person-group><article-title>Neuroprotective effect of naringenin is mediated through suppression of NF-&#x003ba;B signaling pathway in experimental stroke</article-title><source>Neuroscience</source><year>2013</year><volume>230</volume><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.10.041</pub-id><pub-id pub-id-type="pmid">23103795</pub-id></element-citation></ref><ref id="B129-plants-09-01784"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Protective effect of naringenin in experimental ischemic stroke: Down-regulated NOD2, RIP2, NF-&#x003ba;B, MMP-9 and up-regulated claudin-5 expression</article-title><source>Neurochem. Res.</source><year>2014</year><volume>39</volume><fpage>1405</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1007/s11064-014-1326-y</pub-id><pub-id pub-id-type="pmid">24842554</pub-id></element-citation></ref><ref id="B130-plants-09-01784"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chtourou</surname><given-names>Y.</given-names></name><name><surname>Fetoui</surname><given-names>H.</given-names></name><name><surname>Gdoura</surname><given-names>R.</given-names></name></person-group><article-title>Protective effects of naringenin on iron-overload-induced cerebral cortex neurotoxicity correlated with oxidative stress</article-title><source>Biol. Trace Elem. Res.</source><year>2014</year><volume>158</volume><fpage>376</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1007/s12011-014-9948-0</pub-id><pub-id pub-id-type="pmid">24682942</pub-id></element-citation></ref><ref id="B131-plants-09-01784"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.B.</given-names></name><name><surname>Khan</surname><given-names>M.M.</given-names></name><name><surname>Khan</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>M.E.</given-names></name><name><surname>Ishrat</surname><given-names>T.</given-names></name><name><surname>Tabassum</surname><given-names>R.</given-names></name><name><surname>Islam</surname><given-names>F.</given-names></name></person-group><article-title>Naringenin ameliorates Alzheimer&#x02019;s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model</article-title><source>Neurochem. Int.</source><year>2012</year><volume>61</volume><fpage>1081</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2012.07.025</pub-id><pub-id pub-id-type="pmid">22898296</pub-id></element-citation></ref><ref id="B132-plants-09-01784"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liaquat</surname><given-names>L.</given-names></name><name><surname>Batool</surname><given-names>Z.</given-names></name><name><surname>Sadir</surname><given-names>S.</given-names></name><name><surname>Rafiq</surname><given-names>S.</given-names></name><name><surname>Shahzad</surname><given-names>S.</given-names></name><name><surname>Perveen</surname><given-names>T.</given-names></name><name><surname>Haider</surname><given-names>S.</given-names></name></person-group><article-title>Naringenin-induced enhanced antioxidant defence system meliorates cholinergic neurotransmission and consolidates memory in male rats</article-title><source>Life Sci.</source><year>2017</year><volume>194</volume><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2017.12.034</pub-id><?supplied-pmid 29287782?><pub-id pub-id-type="pmid">29287782</pub-id></element-citation></ref><ref id="B133-plants-09-01784"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>I.</given-names></name><name><surname>Bala</surname><given-names>K.</given-names></name><name><surname>Wani</surname><given-names>A.</given-names></name><name><surname>Makhdoomi</surname><given-names>U.</given-names></name><name><surname>Malik</surname><given-names>F.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name></person-group><article-title>Arginase purified from endophytic Pseudomonas aeruginosa IH2: Induce apoptosis through both cell cycle arrest and MMP loss in human leukemic HL-60 cells</article-title><source>Chem. Biol. Interact.</source><year>2017</year><volume>274</volume><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2017.07.001</pub-id><?supplied-pmid 28690100?><pub-id pub-id-type="pmid">28690100</pub-id></element-citation></ref><ref id="B134-plants-09-01784"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bala</surname><given-names>K.</given-names></name><name><surname>Husain</surname><given-names>I.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name></person-group><article-title>Arginine deaminase from Pseudomonas aeruginosa PS2: Purification, biochemical characterization and in vitro evaluation of anticancer activity</article-title><source>3 Biotech</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s13205-020-02212-6</pub-id><?supplied-pmid 32373418?><pub-id pub-id-type="pmid">32373418</pub-id></element-citation></ref><ref id="B135-plants-09-01784"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orhan</surname><given-names>I.</given-names></name><name><surname>Nabavi</surname><given-names>S.</given-names></name><name><surname>Daglia</surname><given-names>M.C.</given-names></name><name><surname>Tenore</surname><given-names>G.</given-names></name><name><surname>Mansouri</surname><given-names>K.</given-names></name><name><surname>Nabavi</surname><given-names>S.</given-names></name></person-group><article-title>Naringenin and atherosclerosis: A review of literature</article-title><source>Curr. Pharm. Biotechnol.</source><year>2015</year><volume>16</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.2174/1389201015666141202110216</pub-id><pub-id pub-id-type="pmid">25483717</pub-id></element-citation></ref><ref id="B136-plants-09-01784"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arafa</surname><given-names>H.M.</given-names></name><name><surname>Abd-Ellah</surname><given-names>M.F.</given-names></name><name><surname>Hafez</surname><given-names>H.F.</given-names></name></person-group><article-title>Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats</article-title><source>J. Egypt Natl. Canc. Inst.</source><year>2015</year><volume>17</volume><fpage>291</fpage><lpage>300</lpage></element-citation></ref><ref id="B137-plants-09-01784"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>F.</given-names></name><name><surname>Lou</surname><given-names>H.</given-names></name></person-group><article-title>Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes</article-title><source>Food Chem. Toxicol.</source><year>2008</year><volume>46</volume><fpage>3140</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2008.06.086</pub-id><pub-id pub-id-type="pmid">18652870</pub-id></element-citation></ref><ref id="B138-plants-09-01784"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>V.C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Z.H.</given-names></name></person-group><article-title>Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress</article-title><source>Biol. Pharm. Bull.</source><year>2013</year><volume>36</volume><fpage>1549</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1248/bpb.b13-00247</pub-id><pub-id pub-id-type="pmid">23912743</pub-id></element-citation></ref><ref id="B139-plants-09-01784"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L.M.</given-names></name><name><surname>Ma</surname><given-names>H.J.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Kong</surname><given-names>Q.Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>The cardioprotective effect of naringenin against ischemia&#x02013;reperfusion injury through activation of ATP-sensitive potassium channel in rat</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2016</year><volume>94</volume><fpage>973</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1139/cjpp-2016-0008</pub-id><pub-id pub-id-type="pmid">27408985</pub-id></element-citation></ref><ref id="B140-plants-09-01784"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testai</surname><given-names>L.</given-names></name><name><surname>Martelli</surname><given-names>A.</given-names></name><name><surname>Marino</surname><given-names>A.</given-names></name><name><surname>Antongiovanni</surname><given-names>V.</given-names></name><name><surname>Ciregia</surname><given-names>F.</given-names></name><name><surname>Giusti</surname><given-names>L.</given-names></name><name><surname>Calderone</surname><given-names>V.</given-names></name></person-group><article-title>The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury</article-title><source>Biochem. Pharmacol.</source><year>2013</year><volume>85</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.03.018</pub-id><pub-id pub-id-type="pmid">23567997</pub-id></element-citation></ref><ref id="B141-plants-09-01784"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccirillo</surname><given-names>G.</given-names></name><name><surname>Magr&#x000ec;</surname><given-names>D.</given-names></name><name><surname>Matera</surname><given-names>S.</given-names></name><name><surname>Magnanti</surname><given-names>M.</given-names></name><name><surname>Pasquazzi</surname><given-names>E.</given-names></name><name><surname>Schifano</surname><given-names>E.</given-names></name><name><surname>Paroli</surname><given-names>M.</given-names></name></person-group><article-title>Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects</article-title><source>Transl. Res.</source><year>2008</year><volume>151</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2008.03.002</pub-id><pub-id pub-id-type="pmid">18433709</pub-id></element-citation></ref><ref id="B142-plants-09-01784"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name></person-group><article-title>Naringenin attenuates pressure overload-induced cardiac hypertrophy</article-title><source>Exp. Ther. Med.</source><year>2015</year><volume>10</volume><fpage>2206</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.3892/etm.2015.2816</pub-id><?supplied-pmid 26668617?><pub-id pub-id-type="pmid">26668617</pub-id></element-citation></ref><ref id="B143-plants-09-01784"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>You</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Naringin inhibits high glucose-induced cardiomyocyte apoptosis by attenuating mitochondrial dysfunction and modulating the activation of the p38 signaling pathway</article-title><source>Int. J. Mol. Med.</source><year>2013</year><volume>32</volume><fpage>396</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1403</pub-id><?supplied-pmid 23732220?><pub-id pub-id-type="pmid">23732220</pub-id></element-citation></ref><ref id="B144-plants-09-01784"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moj&#x0017e;i&#x00161;ov&#x000e1;</surname><given-names>G.</given-names></name><name><surname>&#x00160;ari&#x00161;sk&#x000fd;</surname><given-names>M.</given-names></name><name><surname>Mirossay</surname><given-names>L.</given-names></name><name><surname>Martinka</surname><given-names>P.</given-names></name><name><surname>Moj&#x0017e;is</surname><given-names>J.</given-names></name></person-group><article-title>Effect of Flavonoids on Daunorubicin-induced Toxicity in H9c2 Cardiomyoblasts</article-title><source>Phytother. Res.</source><year>2009</year><volume>23</volume><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/ptr.2566</pub-id><?supplied-pmid 18803248?><pub-id pub-id-type="pmid">18803248</pub-id></element-citation></ref><ref id="B145-plants-09-01784"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulvihill</surname><given-names>E.E.</given-names></name><name><surname>Assini</surname><given-names>S.B.G.</given-names></name><name><surname>DiMattia</surname><given-names>A.S.</given-names></name><name><surname>Khami</surname><given-names>M.</given-names></name><name><surname>Koppes</surname><given-names>J.B.</given-names></name><name><surname>Huff</surname><given-names>M.W.</given-names></name></person-group><article-title>Naringenin decreases progression of atherosclerosis by improving dyslipidemia in highfatfed lowdensity lipoprotein receptornull mice</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2010</year><volume>30</volume><fpage>742</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.109.201095</pub-id><?supplied-pmid 20110573?><pub-id pub-id-type="pmid">20110573</pub-id></element-citation></ref><ref id="B146-plants-09-01784"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soetikno</surname><given-names>V.</given-names></name><name><surname>Arozal</surname><given-names>W.</given-names></name><name><surname>Louisa</surname><given-names>M.</given-names></name><name><surname>Setiabudy</surname><given-names>R.</given-names></name></person-group><article-title>New insight into the molecular drug target of diabetic nephropathy</article-title><source>Int. J. Endocrinol.</source><year>2014</year><volume>2014</volume><fpage>968681</fpage><pub-id pub-id-type="doi">10.1155/2014/968681</pub-id><?supplied-pmid 24648839?><pub-id pub-id-type="pmid">24648839</pub-id></element-citation></ref><ref id="B147-plants-09-01784"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arozal</surname><given-names>W.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Veeraveedu</surname><given-names>P.T.</given-names></name><name><surname>Thandavarayan</surname><given-names>R.A.</given-names></name><name><surname>Sukumaran</surname><given-names>V.</given-names></name><name><surname>Aizawa</surname><given-names>Y.</given-names></name></person-group><article-title>Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-&#x003b3; agonist actions</article-title><source>Toxicology</source><year>2011</year><volume>279</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2010.09.013</pub-id><pub-id pub-id-type="pmid">20888384</pub-id></element-citation></ref><ref id="B148-plants-09-01784"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteban</surname><given-names>V.</given-names></name><name><surname>Lorenzo</surname><given-names>O.</given-names></name><name><surname>Rup&#x000e9;rez</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Mezzano</surname><given-names>S.</given-names></name><name><surname>Blanco</surname><given-names>J.</given-names></name><name><surname>Ruiz-Ortega</surname><given-names>M.</given-names></name></person-group><article-title>Angiotensin II, via AT1 and AT2 receptors and NF-&#x003ba;B pathway, regulates the inflammatory response in unilateral ureteral obstruction</article-title><source>J. Am. Soc. Nephrol.</source><year>2004</year><volume>15</volume><fpage>1514</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000130564.75008.F5</pub-id><pub-id pub-id-type="pmid">15153562</pub-id></element-citation></ref><ref id="B149-plants-09-01784"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozbek</surname><given-names>E.</given-names></name><name><surname>Ilbey</surname><given-names>Y.O.</given-names></name><name><surname>Ozbek</surname><given-names>M.</given-names></name><name><surname>Simsek</surname><given-names>A.</given-names></name><name><surname>Cekmen</surname><given-names>M.</given-names></name><name><surname>Somay</surname><given-names>A.</given-names></name></person-group><article-title>Melatonin attenuates unilateral ureteral obstruction&#x02013;induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression</article-title><source>J. Endourol.</source><year>2009</year><volume>23</volume><fpage>1165</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1089/end.2009.0035</pub-id><pub-id pub-id-type="pmid">19530942</pub-id></element-citation></ref><ref id="B150-plants-09-01784"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karuppagounder</surname><given-names>V.</given-names></name><name><surname>Arumugam</surname><given-names>S.</given-names></name><name><surname>Thandavarayan</surname><given-names>R.A.</given-names></name><name><surname>Pitchaimani</surname><given-names>V.</given-names></name><name><surname>Sreedhar</surname><given-names>R.</given-names></name><name><surname>Afrin</surname><given-names>R.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name></person-group><article-title>Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NF&#x003ba;B p65 mediated inflammation</article-title><source>Int. Immunopharmacol.</source><year>2015</year><volume>28</volume><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.05.050</pub-id><pub-id pub-id-type="pmid">26072060</pub-id></element-citation></ref><ref id="B151-plants-09-01784"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouad</surname><given-names>A.A.</given-names></name><name><surname>Albuali</surname><given-names>W.H.</given-names></name><name><surname>Zahran</surname><given-names>A.</given-names></name><name><surname>Gomaa</surname><given-names>W.</given-names></name></person-group><article-title>Protective effect of naringenin against gentamicin-induced nephrotoxicity in rats</article-title><source>Environ. Toxicol. Pharmacol.</source><year>2014</year><volume>38</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2014.07.015</pub-id><pub-id pub-id-type="pmid">25128772</pub-id></element-citation></ref><ref id="B152-plants-09-01784"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badary</surname><given-names>O.A.</given-names></name><name><surname>Abdel-Maksoud</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>W.A.</given-names></name><name><surname>Owieda</surname><given-names>G.H.</given-names></name></person-group><article-title>Naringenin attenuates cisplatin nephrotoxicity in rats</article-title><source>Life Sci.</source><year>2005</year><volume>76</volume><fpage>2125</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2004.11.005</pub-id><?supplied-pmid 15826879?><pub-id pub-id-type="pmid">15826879</pub-id></element-citation></ref><ref id="B153-plants-09-01784"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrezenmeier</surname><given-names>E.V.</given-names></name><name><surname>Barasch</surname><given-names>J.</given-names></name><name><surname>Budde</surname><given-names>K.</given-names></name><name><surname>Westhoff</surname><given-names>T.</given-names></name><name><surname>Schmidt-Ott</surname><given-names>K.M.</given-names></name></person-group><article-title>Biomarkers in acute kidney injury&#x02014;Pathophysiological basis and clinical performance</article-title><source>Acta Physiol.</source><year>2017</year><volume>219</volume><fpage>554</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1111/apha.12764</pub-id><?supplied-pmid 27474473?><pub-id pub-id-type="pmid">27474473</pub-id></element-citation></ref><ref id="B154-plants-09-01784"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>C.H.A.</given-names></name><name><surname>Huang</surname><given-names>C.C.</given-names></name><name><surname>Tsai</surname><given-names>F.Y.</given-names></name><name><surname>Lee</surname><given-names>J.Y.C.</given-names></name><name><surname>Cheng</surname><given-names>S.M.</given-names></name><name><surname>Chang</surname><given-names>Y.C.</given-names></name><name><surname>Chang</surname><given-names>J.Y.</given-names></name></person-group><article-title>Survivin&#x02013;biology and potential as a therapeutic target in oncology</article-title><source>OncoTargets Ther.</source><year>2013</year><volume>6</volume><fpage>1453</fpage><pub-id pub-id-type="doi">10.2147/OTT.S33374</pub-id><?supplied-pmid 24204160?><pub-id pub-id-type="pmid">24204160</pub-id></element-citation></ref><ref id="B155-plants-09-01784"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>M.M.</given-names></name><name><surname>Banik</surname><given-names>N.L.</given-names></name><name><surname>Ray</surname><given-names>S.K.</given-names></name></person-group><article-title>Survivin knockdown increased anti-cancer effects of (&#x02212;)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells</article-title><source>Exp. Cell Res.</source><year>2012</year><volume>318</volume><fpage>1597</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2012.03.033</pub-id><pub-id pub-id-type="pmid">22507272</pub-id></element-citation></ref><ref id="B156-plants-09-01784"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orrego-Lagar&#x000f3;n</surname><given-names>N.</given-names></name><name><surname>Mart&#x000ed;nez-Hu&#x000e9;lamo</surname><given-names>M.</given-names></name><name><surname>Vallverd&#x000fa;-Queralt</surname><given-names>A.</given-names></name><name><surname>Lamuela-Raventos</surname><given-names>R.M.</given-names></name><name><surname>Escribano-Ferrer</surname><given-names>E.</given-names></name></person-group><article-title>High gastrointestinal permeability and local metabolism of naringenin: Influence of antibiotic treatment on absorption and metabolism</article-title><source>Br. J. Nutr.</source><year>2015</year><volume>114</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1017/S0007114515001671</pub-id><pub-id pub-id-type="pmid">26083965</pub-id></element-citation></ref><ref id="B157-plants-09-01784"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Kolosov</surname><given-names>V.</given-names></name><name><surname>Perelman</surname><given-names>J.</given-names></name></person-group><article-title>Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-&#x003ba;B activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells</article-title><source>Mol. Cell. Biochem.</source><year>2011</year><volume>351</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s11010-010-0708-y</pub-id><pub-id pub-id-type="pmid">21229383</pub-id></element-citation></ref><ref id="B158-plants-09-01784"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Rejaie</surname><given-names>S.S.</given-names></name><name><surname>Abuohashish</surname><given-names>H.M.</given-names></name><name><surname>Al-Enazi</surname><given-names>M.M.</given-names></name><name><surname>Al-Assaf</surname><given-names>A.H.</given-names></name><name><surname>Parmar</surname><given-names>M.Y.</given-names></name><name><surname>Ahmed</surname><given-names>M.M.</given-names></name></person-group><article-title>Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats</article-title><source>World J. Gastroenterol.</source><year>2013</year><volume>19</volume><fpage>5633</fpage><lpage>5644</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i34.5633</pub-id><pub-id pub-id-type="pmid">24039355</pub-id></element-citation></ref><ref id="B159-plants-09-01784"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dou</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>E.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Mani</surname><given-names>S.</given-names></name></person-group><article-title>Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-&#x003ba;B signalling</article-title><source>Br. J. Nutr.</source><year>2013</year><volume>110</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1017/S0007114512005594</pub-id><pub-id pub-id-type="pmid">23506745</pub-id></element-citation></ref><ref id="B160-plants-09-01784"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manabe</surname><given-names>N.</given-names></name><name><surname>Wong</surname><given-names>B.S.</given-names></name><name><surname>Camilleri</surname><given-names>M.</given-names></name></person-group><article-title>New-generation 5-HT4 receptor agonists: Potential for treatment of gastrointestinal motility disorders</article-title><source>Expert Opin. Investig. Drugs</source><year>2010</year><volume>19</volume><fpage>765</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1517/13543784.2010.482927</pub-id></element-citation></ref><ref id="B161-plants-09-01784"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>T.L.</given-names></name></person-group><article-title>Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders</article-title><source>Curr. Opin. Pharmacol.</source><year>2006</year><volume>6</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2006.08.005</pub-id><pub-id pub-id-type="pmid">17011824</pub-id></element-citation></ref><ref id="B162-plants-09-01784"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Oh</surname><given-names>J.</given-names></name><name><surname>Hong</surname><given-names>G.S.</given-names></name><name><surname>Seo</surname><given-names>E.K.</given-names></name><name><surname>Oh</surname><given-names>U.</given-names></name><name><surname>Shim</surname><given-names>W.S.</given-names></name></person-group><article-title>Ghrelin receptor is activated by naringin and naringenin, constituents of a prokinetic agent Poncirus fructus</article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>148</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.04.039</pub-id><?supplied-pmid 23639361?><pub-id pub-id-type="pmid">23639361</pub-id></element-citation></ref><ref id="B163-plants-09-01784"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name></person-group><article-title>Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway</article-title><source>Tumor Biol.</source><year>2016</year><volume>37</volume><fpage>11365</fpage><lpage>11374</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5013-2</pub-id><?supplied-pmid 26960693?><pub-id pub-id-type="pmid">26960693</pub-id></element-citation></ref><ref id="B164-plants-09-01784"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Shang</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells</article-title><source>Exp. Ther. Med.</source><year>2016</year><volume>11</volume><fpage>669</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.3892/etm.2015.2912</pub-id><?supplied-pmid 26893664?><pub-id pub-id-type="pmid">26893664</pub-id></element-citation></ref><ref id="B165-plants-09-01784"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>L.H.</given-names></name><name><surname>Hon</surname><given-names>C.M.</given-names></name><name><surname>Chellappan</surname><given-names>D.K.</given-names></name><name><surname>Chellian</surname><given-names>J.</given-names></name><name><surname>Madheswaran</surname><given-names>T.</given-names></name><name><surname>Zeeshan</surname><given-names>F.</given-names></name><name><surname>Awasthi</surname><given-names>R.</given-names></name><name><surname>Aljabali</surname><given-names>A.A.</given-names></name><name><surname>Tambuwala</surname><given-names>M.M.</given-names></name><name><surname>Dureja</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Molecular mechanisms of action of naringenin in chronic airway diseases</article-title><source>Eur. J. Pharmacol.</source><year>2020</year><volume>879</volume><fpage>173139</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173139</pub-id><pub-id pub-id-type="pmid">32343971</pub-id></element-citation></ref><ref id="B166-plants-09-01784"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>T.</given-names></name></person-group><article-title>The nuclear factor NF-kappaB pathway in inflammation</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2009</year><volume>1</volume><fpage>a001651</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a001651</pub-id><pub-id pub-id-type="pmid">20457564</pub-id></element-citation></ref><ref id="B167-plants-09-01784"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T.M.</given-names></name><name><surname>Paudel</surname><given-names>K.R.</given-names></name><name><surname>Kim</surname><given-names>D.W.</given-names></name></person-group><article-title>Eriobotrya japonica leaf extract attenuates airway inflammation in ovalbumin-induced mice model of asthma</article-title><source>J. Ethnopharmacol.</source><year>2020</year><volume>253</volume><fpage>112082</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.112082</pub-id><pub-id pub-id-type="pmid">31310829</pub-id></element-citation></ref><ref id="B168-plants-09-01784"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorniak</surname><given-names>I.</given-names></name><name><surname>Bartoszewski</surname><given-names>R.</given-names></name><name><surname>Kroliczewski</surname><given-names>J.</given-names></name></person-group><article-title>Comprehensive review of antimicrobial activities of plant flavonoids</article-title><source>Phytochem. Rev.</source><year>2019</year><volume>18</volume><fpage>241</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s11101-018-9591-z</pub-id></element-citation></ref><ref id="B169-plants-09-01784"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koz&#x00142;owska</surname><given-names>J.</given-names></name><name><surname>Potaniec</surname><given-names>B.</given-names></name><name><surname>&#x0017b;arowska</surname><given-names>B.</given-names></name><name><surname>Anio&#x00142;</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis and Biological Activity of Novel O-Alkyl Derivatives of Naringenin and Their Oximes</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1485</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22091485</pub-id></element-citation></ref><ref id="B170-plants-09-01784"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duda-Madej</surname><given-names>A.</given-names></name><name><surname>Koz&#x00142;owska</surname><given-names>J.</given-names></name><name><surname>Krzy&#x0017c;ek</surname><given-names>P.</given-names></name><name><surname>Anio&#x00142;</surname><given-names>M.</given-names></name><name><surname>Seniuk</surname><given-names>A.</given-names></name><name><surname>Jermakow</surname><given-names>K.</given-names></name><name><surname>Dworniczek</surname><given-names>E.</given-names></name></person-group><article-title>Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3642</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25163642</pub-id></element-citation></ref><ref id="B171-plants-09-01784"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran Trung</surname><given-names>H.</given-names></name><name><surname>Truong Thi Huynh</surname><given-names>H.</given-names></name><name><surname>Nguyen Thi Thuy</surname><given-names>L.</given-names></name><name><surname>Nguyen Van Minh</surname><given-names>H.</given-names></name><name><surname>Thi Nguyen</surname><given-names>M.N.</given-names></name><name><surname>Luong Thi</surname><given-names>M.N.</given-names></name></person-group><article-title>Growth-Inhibiting, Bactericidal, Antibiofilm, and Urease Inhibitory Activities of Hibiscus rosa sinensis L. Flower Constituents toward Antibiotic Sensitive- and Resistant-Strains of Helicobacter pylori</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>20080</fpage><lpage>20089</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c01640</pub-id><pub-id pub-id-type="pmid">32832762</pub-id></element-citation></ref><ref id="B172-plants-09-01784"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vikram</surname><given-names>A.</given-names></name><name><surname>Jayaprakasha</surname><given-names>G.K.</given-names></name><name><surname>Jesudhasan</surname><given-names>P.R.</given-names></name><name><surname>Pillai</surname><given-names>S.D.</given-names></name><name><surname>Patil</surname><given-names>B.S.</given-names></name></person-group><article-title>Suppression of bacterial cell-cell signalling, biofilm formation and type III secretion system by citrus flavonoids</article-title><source>J. Appl. Microbiol.</source><year>2010</year><volume>109</volume><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2010.04677.x</pub-id><?supplied-pmid 20163489?><pub-id pub-id-type="pmid">20163489</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="plants-09-01784-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Naringin is hydrolyzed by naringinase and &#x003b1;-L-rhamnosidase into prunin and rhamnose. With the help of &#x003b2;-d-glucosidase, prunin then is hydrolyzed into &#x0201c;Naringenin,&#x0201d; which is absorbed into the intestinal tract after being hydrolyzed by naringinase.</p></caption><graphic xlink:href="plants-09-01784-g001"/></fig><fig id="plants-09-01784-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Different pharmacological activities of Naringenin.</p></caption><graphic xlink:href="plants-09-01784-g002"/></fig><fig id="plants-09-01784-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Naringenin found in citrus fruits is a flavonoid that has anti-cancer properties.</p></caption><graphic xlink:href="plants-09-01784-g003"/></fig><fig id="plants-09-01784-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Different mechanisms involved in metabolic disorders such as diabetes and the role of naringenin in the regulation of several pathways involved in metabolic syndrome.</p></caption><graphic xlink:href="plants-09-01784-g004"/></fig></floats-group></article>